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INTRODUCTION
Origin
Cancer in children under 15 years of age is rare, accounting for
less than 1% of malignancies diagnosed each year in developed
countries (Draper, 1995; Coleman et al, 1999). The types of
cancer that occur in children are generally more responsive to
chemotherapy than those in adults and, in recent years, improved
treatment protocols have resulted in significant increases in
survival for a wide range of diagnostic groups. These improve-
ments have been particularly marked for leukaemia, which
accounts for around a third of all childhood malignancies, and
more than 70% of children diagnosed in the UK with this once
rapidly fatal disease now survive into adulthood (Draper, 1995;
Coleman et al, 1999). Cancer in children, nevertheless, remains a
significant health problem. Of the 10 million children in the UK,
around 1200 (one in every 8000) are diagnosed with the disease
each year: about one child in every 600 developing it before their
15th birthday (Parkin et al, 1998; Coleman et al, 1999). Despite
the marked improvements in treatment, about one in ten of all
childhood deaths occurring after the first month of life is attributed
to cancer and among 5– to 14-year-olds cancer is the second most
common cause of death, after accidents (Botting and Crawley,
1995; Fear et al, 1999). Unfortunately, the marked advance in
childhood cancer treatment seen over the last 20 years has not been
matched by similar advances in knowledge of its aetiology and the
causes of the majority of childhood cancers remain unknown
(Draper et al, 1995; Miller et al, 1995; Little, 1999).
When, in 1990, this situation was discussed informally by
members of the Radiation and Cancer Subcommittee of the
United Kingdom Coordinating Committee on Cancer Research
(UKCCCR) the Advisory Group on Non-Ionising Radiation of the
National Radiological Protection Board (NRPB) and the Medical
and Scientific Advisory Panel of the Leukaemia Research Fund
(LRF), the only known causes apart from the hereditary factors
that caused a few cases, were exposure to X-rays in utero or after
birth, some types of chemotherapy given for a previous cancer,
and infection with the Epstein–Barr virus. Many ideas had been
floated, but often without distinguishing between the different
types of the disease. Leukaemia had been the most extensively
studied, although not always by sub-type. Among the many
possible causes that had been suggested for leukaemia (or more
specifically, in some studies for acute lymphoblastic leukaemia
(ALL)) were: (1) exposure of the father to ionizing radiation
before the child’s conception (Gardner et al, 1990), or to a variety
of other agents in the occupational and home environments
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1986; Lowengart et al, 1987); (2) exposure of the fetus transpla-
centally to a variety of N-nitroso compounds (Magee et al, 1976)
or infection (Knox et al, 1983); and (3) exposure of the child post-
natally to radon in house air (Henshaw et al, 1990) and to chlor-
amphenicol given therapeutically (Shu et al, 1987). A history of
viral infections (McKinney et al, 1987) and of infection arising
from the mixing of urban and rural populations (Kinlen, 1988;
Kinlen et al, 1990), or following a paucity of common infections
in infancy (Greaves, 1988) and a deficit of immunizations (Kneale
et al, 1986; McKinney et al, 1987) had also been associated with
the disease.
Specific exposures suggested for specific sites or types of
cancer other than ALL had, by 1990, included: chloramphenicol
(Shu et al, 1987) and maternal drug use prior to or during preg-
nancy in relation to acute non-lymphoblastic leukaemia (Robison
et al, 1989) barbiturates, and parental exposure to substances
such as solvents (Gold and Gordis, 1978; Gold et al, 1979) and
N-nitroso compounds (Preston-Martin et al, 1982) for central
nervous system (CNS) tumours; and maternal exposures during or
just prior to pregnancy to drugs (including recreational drugs and
anti-convulsants), alcohol and hair colourants for neuroblastoma
(Lipson and Bale, 1985; Kramer et al, 1987) and for Wilms’
tumour (Bunin et al, 1987). It had also been suggested that
Hodgkin’s disease in children might arise as a rare sequel to infec-
tion with a common virus (Gutensohn and Cole, 1981; Gutensohn
and Shapiro, 1982) and that children with rhabdomyosarcoma
were less likely to be immunized than controls (Grufferman et al,
1982; Hartley et al, 1988).
For childhood cancer more generally, exposure to extremely
low frequency electromagnetic fields from the passage of elec-
tricity (Wertheimer and Leeper, 1979) and the administration of
vitamin K within the first week of life (Golding et al, 1990) had
also been suggested as having a role.
Objectives
It seemed, therefore, that it would be scientifically, socially and
economically sensible to mount a national study of all types of
childhood cancer on a large enough scale to provide sufficient data
to test adequately the major hypotheses about the possible causes
of such cancers, excluding only wide-ranging family studies of
genetic factors.
After detailed discussions, five broad hypotheses were defined
that the study should attempt to test. These were that childhood
cancer might be caused by:
1. a child’s exposure to ionizing radiation (natural or man-made)
either during the mother’s pregnancy or after birth
2. similar exposure to potentially hazardous chemicals, some of
which have been associated with specific cancers in adult life
3. exposure of the parental germ cells to either radiation or
hazardous chemicals before the child’s conception
4. extremely low frequency electromagnetic fields post-natally,
particularly in the case of brain cancers and leukaemia
5. in the special case of leukaemias and lymphomas, abnormal
responses to one or more common infectious agents.
Two specific hypotheses were considered within the umbrella
explanation of the fifth hypothesis. First, some subtypes (in partic-
ular common ALL) follow (i) paucity of infectious exposure in
infancy, and (ii) late or delayed exposure shortly before the onset
of symptoms (3–12 months prior to diagnosis). Secondly, the risk
of leukaemia (and possibly lymphoma) is increased in children in
rural areas of marked population mixing. In either case, the
leukaemia may also be associated with genetic factors that influ-
ence the immune response – in particular, HLA class II alleles or
haplotype.
Organization
A management committee was consequently set up comprising
epidemiologists, paediatric oncologists, laboratory scientists and a
representative of the NRPB, the members of which planned the
conduct of the study under the aegis of the UKCCCR. The
committee divided England & Wales into the nine regions shown
in Figure 1, each of which became the responsibility of a leading
epidemiologist who, in conjunction with local paediatric oncolo-
gists and the help of the UK Children’s Cancer Study Group,
arranged for the collection of the necessary information.
A similar study was initiated independently at about the same
time in Scotland under the aegis of the Scottish Department of
Health. Early contacts enabled it to be agreed that similar data
would be collected in much the same way both in Scotland and in
England & Wales, that the principal Scottish investigator would
join the Management Committee and that the principal results
obtained in all three countries would be pooled for central
analysis. Consequently Scotland became, in effect, the tenth
region in a study, named the United Kingdom Childhood Cancer
Study (UKCCS), that covered the whole of the UK, apart from
Northern Ireland.
With the rare exceptions described in the section on General
Methodology, the study was planned to include all children up to
15 years of age registered with a Family Health Services Authority
(FHSA) in England & Wales and with a Health Board (HB) in
Scotland who were diagnosed as having cancer. Case accrual
began in Scotland on 1 January 1991 and in England & Wales on
1 April 1992 and was planned to continue until at least 1000 cases
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Figure 1 Regional study centres. SC, Scotland; NE, North-east; NW,
North-west; TR, Trent; CE, Central; EA, East Anglia; SM, South Midlands;
SWA, South-Wales; SW, South-west; SE, South-eastof ALL had been studied, which it was thought should take about 4
years. In the event, accrual ceased in different areas at different
dates between December 1994 and December 1996. For each child
with cancer, two controls were sought matched on sex and month
and year of birth from the same FHSA or HB list as that on which
the child with cancer had been registered before the cancer was
diagnosed. Altogether the study included 1461 children with acute
lymphoblastic leukaemia, 2377 children with other types of cancer
and 7629 control children (47 children with cancer having only
one control).
Details of the information obtained and how it was collected are
described in sections on materials and general methodology,
electromagnetic fields, radon and terrestrial gamma radiation, clas-
sification of solid tumours, biological samples and classification of
leukaemia, and genetic susceptibility.
MATERIALS AND GENERAL METHODOLOGY
The ten UKCCS data collection centres (Figure 1) were respon-
sible for all aspects of regional study organization including the
day-to-day running of the study, obtaining permission from local
ethical committees and liaising with appropriate health care
professionals. An outline of a typical organizational chart for data
collection is given in Figure 2.
A common protocol was agreed by the Management Committee
at the outset of the study. The need to respond at a local level to
prevailing circumstances – such as specific requests by local
ethical committees etc. – resulted in a certain amount of regional
variation. The main departures from the protocol, together with
basic regional information, are listed by region in Table 1.
Subjects
In England & Wales, the UKCCS study population was defined as
children (0–14 years) registered with one of the 98 FHSAs. Under
the National Health Service, all General Practitioners (GPs) and
their patients are registered with their local FHSA. This comprises
around 98% of the total population (RCGP, 1987). In Scotland,
where the system is similar but independent, the study population
was defined as children registered with one of the 15 Health
Boards (HBs) and has been described separately (McKinney et al,
1995).
Cases
The study began in Scotland on 1 January 1991 and on 1 April or 1
September 1992 in the regions of England & Wales (see Table 1).
Following these start dates, children registered with an FHSA/HB
who were diagnosed either with a confirmed malignancy or with
any tumour of the CNS, as defined in the classification scheme
devised by Birch and Marsden (1987), were potentially eligible for
the study. In Scotland, case accrual ceased in December 1994, and
in England & Wales it was restricted in all regions to patients with
leukaemia and non-Hodgkin’s lymphoma throughout 1995, and
leukaemia alone throughout 1996.
Each regional centre was responsible for ensuring the complete-
ness of ascertainment of cases diagnosed in residents within their
boundaries. The majority of cases were notified directly from
regional treatment centres by paediatric oncologists belonging to
the UKCCSG (Mott et al, 1997). In other hospitals, and certain
specialist units that treated adults as well as children, individually
UK Childhood Cancer Study 1075
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Figure 2 Study organization and main components. EMF, extremely low frequency electromagnetic fieldstailored referral systems were put in place. In addition, cross-
checks were made against regional cancer registries and against
the National Registry of Childhood Tumours (NRCT) (Stiller et al,
1995).
Detailed diagnostic information was obtained from multiple
sources. For leukaemias, the principal diagnostic sources were the
Medical Research Council’s treatment trials (MRC, 1997, 1998).
Information about leukaemic children who were not enrolled in
trials was obtained from one of three sources: the UKCCSG, the
NRCT, or the individual consultant treating the child. In addition,
cytogenetic data on trial and non-trial patients were obtained from
the Leukaemia Research Fund’s cytogenetics database held at the
Royal Free Hospital (Moorman et al, 1996), and molecular diag-
nostic information on patients with ALL was provided by the
central reference laboratory for UKCCS pretreatment samples
at the Leukaemia Research Fund Centre, Institute of Cancer
Research. To obtain reliable information about the diagnosis of
cancers other than leukaemia, a histopathology review database
was specially created for the purposes of the study. Detailed infor-
mation about this database, and the diagnostic verification proce-
dures used, are given later.
Controls
Each case child was individually matched with two control
children of the same sex, date of birth and region of residence. The
mechanism by which this was achieved varied slightly from one
region to another (Table 1).
Throughout the majority of English study regions controls,
matched on sex and age (month and year of birth), were randomly
selected from the same FHSA list as their corresponding case. This
was achieved by obtaining computerized lists of children regis-
tered with each FHSA on 1 January and 1 July each year: the
potential controls being randomly selected from the list on which
the case child had appeared immediately prior to the diagnosis of
the cancer. When the case child was less than 1 year old, however,
controls were chosen from the first FHSA list on which the case
appeared. Because of computing difficulties, two English study
regions did not randomly select potential controls from within the
same birth month as the corresponding case. Instead, the FHSA
downloads were sorted in date of birth order and controls with the
closest birthdates to the case selected (hence, most controls were
born on the same day as their corresponding case) (Table 1).
In Scotland, the system was similar to the main method
described above except that the Health Boards randomly selected
the controls (McKinney et al, 1995). Unfortunately seven of the
eight Welsh FHSAs and one English FHSA declined to participate
in the study. For each case diagnosed within their boundaries the
corresponding control selection had two stages: two GPs were
randomly selected and approached and, if they agreed, potential
controls (of the same sex and born within 3 months of the
corresponding case) were randomly selected from their practice
lists.
Whatever procedure was used to identify potential controls, the
GPs of the first two identified were approached and, with their
permission, the parents of the children were contacted and asked
to participate in the study. When the GP refused permission to
contact, or the parents refused to participate, another control was
selected by the same method, and so on until two control families
participated (Figure 2). All details of control replacements were
logged, and details of non-participating controls retained (see
Registration below).
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Table 1 Case accrual and control selection by study region
Study region Accrual dates (no. of children studied) Control selection
Leukaemia Non-Hodgkin’s Other cancers
lymphoma
Central 09/92–12/96 09/92–12/95 09/92–12/94 As protocol
(153) (23) (140)
East Anglia 04/92–12/96 04/92–12/95 04/92–12/94 Note a
(172) (20) (160)
North East 04/92–12/96 04/92–12/95 04/92–12/94 As protocol
(194) (29) (228)
North West 09/92–12/96 09/92–12/95 09/92–12/94 Note d
(220) (30) (249)
Scotland 01/91–12/94 01/91–12/94 01/91–12/94 Note b
(156) (22) (272)
South East 04/92–03/96 04/92–12/95 04/92–12/94 As protocol
(225) (32) (281)
South Midlands 04/92–12/96 04/92–12/95 04/92–12/94 As protocol
(170) (21) (150)
South Wales 09/92–12/96 09/92–12/95 09/92–12/94 Note c
(53) (9) (38)
South West 04/92–12/96 04/92–12/95 04/92–12/94 Note d
(234) (24) (187)
Trent 04/92–12/96 04/92–12/95 04/92–12/94 Note e
(159) (21) (166)
Notes: aFor cases diagnosed before 9/93 FHSA records ordered by date of birth and same sex and controls with closest
birth-date selected. bAs in protocol but controls selected by the health boards. cEach pair of controls matched on sex and
month of birth (± 3 months) randomly selected from each of two randomly selected GP lists. dOne FHSA withheld
permission for data access. Controls selected as in note c. eFor cases diagnosed before 4/96, controls selected as in
note a.Ethnicity was ignored during control selection, but a third
control family was, where possible, interviewed in place of the
second family when the parents of both control children were of a
different ethnic group to the parents of the case child. In most
regions this additional selection was possible only when the case
was white and the two interviewed controls were not.
Ineligible children
Children (cases and controls) were ineligible if they had been born
outside Great Britain or had a prior malignancy. For the purposes
of the study, all control children were assigned a ‘pseudo-
diagnosis’ date that coincided with the exact age at which their
corresponding case was diagnosed. Children who themselves, or
whose parents, were resident outside Great Britain in the 3 months
leading up to diagnosis/pseudo-diagnosis were considered ineli-
gible. For ethical reasons, children in residential local authority
care at diagnosis/pseudo-diagnosis (< 1% of the total childhood
population) were also excluded from the study.
Data collection
Registration
At registration the date of birth, sex, initial diagnosis and home
address of all eligible cases diagnosed in the regions were
recorded, regardless of whether their families subsequently partici-
pated in the study. Controls were selected only for participating
cases. All control children whose GP was approached were regis-
tered in the system, regardless of whether their GP/parents agreed
to participate. The system was designed so that the origins of all
controls attached to a case were known, the key fields being:
1. Eligibility: yes or no
2. Identification number: chronological order in the selection
sequence
3. Replacement number: identification number of the control
replaced
4. Choice number: 1st, 2nd, etc. (this variable is less than the
identification number when new controls replace ineligible
controls).
For those children whose families were recruited, the address at
diagnosis/pseudo-diagnosis was recorded at registration. For those
whose families did not participate, the initial contact address
supplied by the treating hospital (cases) or listed on the FHSA/HB
database (controls) was recorded.
Participation
Eighty-seven per cent of the parents of the 4433 case children
agreed to be interviewed but only 64% of the 11 987 potentially
eligible control children. The numbers not participating for
different reasons are shown in Figure 3.
A few (3% of the cases and less than 1% of the controls) were
not approached. This occurred when the mother (biological or
non-biological) of the child had died and no suitable surrogate
could be found, when the parents did not speak English and for
whom no suitable translator could be found, or when the family
emigrated shortly after diagnosis/pseudo-diagnosis. For both cases
and controls, parental refusal to participate was the main reason an
interview was not secured, accounting for 279 (47%) of the 595
non-interviewed cases and 2625 (60%) of the 4358 non-inter-
viewed controls. Refusals by medical practitioners to allow their
patients to participate in the study was also important: permission
to approach families was not given by the consultants treating 116
cases and by the GPs of 1012 controls. For controls, another
important factor for not securing an interview was ‘failure to
trace’: the address held by the GP of 648 (5% of the total and 15%
of the not interviewed) was incorrect, and the family’s correct
address was not traceable.
Parental interview
Mothers and fathers were interviewed using separate, but similar,
questionnaires. The parent(s) or guardian(s) with whom the child
was living at the time of diagnosis/pseudo-diagnosis were
approached and interviewed first, regardless of whether they were
the biological or non-biological parent(s). In the case of the latter,
permission was then sought to contact and interview the biological
parent(s).
A trained interviewer using a structured questionnaire inter-
viewed all participating parents. Telephone interviews were
conducted only when face-to-face interviews could not be
arranged. When one parent (usually the father) could not be
contacted, the available parent (usually the mother) was asked to
act as a surrogate.
Full residential and occupational histories, including specific
information about occupational exposures and individual housing
characteristics, were recorded for each parent. To improve the
quality of these data, a form asking parents to list the places where
they had lived and the jobs they had had was sent out in advance of
the interview. At interview, mothers and fathers were also asked
about their own health, social habits and illnesses in their families.
Additional sections on pregnancies and on the index child’s health,
schooling and social history were incorporated into the mother’s
questionnaire.
On completion of the interview, parents were asked whether
they were willing to be contacted again. In particular, consent was
sought for their participation in both the ionizing radiation (radon
and gamma) and the non-ionizing radiation (EMF) components of
the study (Figure 2). Signed agreement was also requested for
blood samples of the cases to be taken at a later date and for
medical and other records to be accessed.
Medical note abstractions
With the interviewee’s and their GP’s permission, the GP notes of
index children and their biological parents were abstracted onto
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Eligible
Not interviewed
Not approached Not traced Refusal
Parental General practitioner Consultant
Interviewed
Cases Controls
4433 (100%) 11 987 (100%)
Cases Controls
595 (13%) 4358 (36%)
Cases Controls
145 (3%) 73 (<1%)
Cases Controls
44 (<1%) 648 (5%)
Cases Controls
279 (>%) 2625 (22%)
Cases Controls
11 (<1%) 1012 (9%)
Cases Controls
116 (3%) 0
Cases Controls
406 (10%) 3637 (31%)
Cases Controls
3838 (87%) 7629 (64%)
Figure 3 Numbers of eligible and participating families and numbers not
participating for different reasonsspecially designed forms: information being collected about past
illnesses, prescribed drug usage, vaccinations received and other
medical procedures. Similarly, details about the mother’s preg-
nancy with the index child were transferred from her obstetric
notes and the index baby’s neonatal notes (where they existed) to
structured obstetric abstraction forms. More information about the
variables included on these forms is given elsewhere (Roman et al,
1997; McKinney et al, 1999).
Ionizing and non-ionizing radiation
The arrangements made for measuring the children’s exposure to
electromagnetic fields and to radon and terrestrial gamma radia-
tion are described on pp. 1087–1090.
Biological samples
After obtaining parental permission, pretreatment blood samples
were sought from all children with cancer, and marrow samples
from all with leukaemia and lymphoma. Following interview,
blood samples were also sought from the case children’s first-
degree relatives or, when appropriate, from the children during
remission. The number of samples collected and what was done
with them are described later.
Data management and census linkage
Registration and interview data were coded and entered into
computers in the regional centres using the database management
system FoxPro version 2.6 (FoxPro, 1991). Parental occupational
histories were coded according to the Office of Population Censuses
and Surveys 1990 schemes (Office of Population Censuses and
Statistics, 1990; Central Statistics Office, 1992; Office of National
Statistics Office, 1998), and illnesses according to the International
Classification of Diseases tenth revision (WHO, 1990, 1992). On
completion of regional checking, the data were further scrutinized,
merged and transferred to Microsoft SQL (structured query
language) Server version 6.5 at the Study’s national centre in Leeds.
At the same time, the regionally collected case registration data
were linked to various national diagnostic and biological databases,
and consequent discrepancies resolved, as described later.
With a view to linking to areal information derived from the
1991 census (Census, 1991), particular attention was paid to
collecting valid postcoded addresses for certain key points in time.
For participants, these included the homes the child lived in at the
time of diagnosis/pseudo-diagnosis and at the time of birth. For
non-participants the only available address was the ‘contact’
address, as held by the FHSA/HB or by the GP. The postcodes of
all addresses were checked and, where necessary, automatically
reassigned using QuickAddress (1999). About 5% of all addresses
could not be resolved in this way, and postcodes were manually
allocated. Each address was then linked to one of the 108 336
enumeration districts (EDs) in England & Wales or 38 084 output
areas (OAs) in Scotland using dictionaries of correspondence
between postcode and census units. The establishment of this
linkage enabled aggregate information derived from the census to
be used as an areal indication of factors such as wealth and popu-
lation density.
The ‘deprivation’ index used in the present report is similar to
that developed for a national study of the geographical distribution
of childhood leukaemia (Draper et al, 1991). For each ED in
England & Wales and OA in Scotland, the following proportions
were calculated:
1. households without a car
2. overcrowded households (more than one person per room)
1078 UK Childhood Cancer Study Investigators
British Journal of Cancer (2000) 82(5), 1073–1102 © 2000 Cancer Research Campaign
Table 2 Characteristics of interviewed cases
Leukaemia Lymphoma
Acute Central nervous Other All
lymphoblastic Other Non-Hodgkin’s Hodgkin’s system tumours cancersa cancers
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 1461 (100) 275 (100) 231 (100) 118 (100) 686 (100) 1067 (100) 3838 (100)
Diagnostic information source
Treatment trial 1313 (89.9) 188 (68.4) – – – – 1501 (39.1)
Histopathology registerb – – 231 (100) 118 (100) 686 (100) 1067 (100) 2102 (54.8)
Other 148 (10.1) 87 (31.6) – – – – 235 (6.1)
Sex
Boys 820 (56.1) 151 (54.9) 167 (72.3) 85 (72.0) 345 (50.3) 586 (54.9) 2154 (56.1)
Girls 641 (43.9) 124 (45.1) 64 (27.7) 33 (28.0) 341 (49.7) 481 (45.1) 1684 (43.9)
Age at diagnosis (years)
0 50 (3.4) 38 (13.8) 0 (0.0) 0 (0.0) 51 (7.4) 177 (16.6) 316 (8.2)
1–4 795 (54.4) 94 (34.2) 53 (22.9) 9 (7.6) 215 (31.3) 438 (41.0) 1604 (41.8)
5–9 394 (27.0) 58 (21.2) 71 (30.7) 36 (30.5) 258 (37.6) 229 (21.5) 1046 (27.3)
10–14 222 (15.2) 85 (30.9) 107 (46.3) 73 (61.9) 162 (23.6) 223 (20.9) 872 (22.7)
Median 4.4 5.4 9.5 11.9 6.4 3.8 5.0
Ethnicity
Whitec 1224 (83.8) 216 (78.5) 197 (85.3) 96 (81.4) 586 (85.4) 896 (84.0) 3215 (83.8)
Year of birth
≤ 1984–1985 313 (21.4) 101 (36.7) 135 (58.4) 89 (75.4) 277 (40.4) 331 (31.1) 1246 (32.5)
1986–1990 647 (44.3) 63 (22.9) 79 (34.1) 28 (23.7) 274 (39.9) 350 (32.8) 1441 (37.5)
³ 1991 501 (34.3) 111 (40.3) 17 (7.3) 1 (0.8) 135 (19.6) 386 (36.1) 1151 (30.0)
Median 1989 1988 1984 1981 1987 1989 1988
aPeripheral neural tumours, retinoblastomas, soft tissue sarcomas, carcinomas, renal tumours, hepatic tumours, bone tumours, Langerhan’s cell histiocytosis
germ cell tumours, and other lympho-reticular and unspecified tumours. bSpecially created for UKCCS (reference histopathology section). cBoth biological
parents White.3. persons unemployed: the denominator being persons who were
‘economically active’ (over 16 years of age, with a potential to
be gainfully employed or in receipt of unemployment benefit).
In simple terms, following a series of standard transformation
procedures, the standard deviation from the mean of each of the
three variables were summed for each area (Townsend et al, 1988).
The 146 420 small areas were then ranked by the resulting ‘depri-
vation’ index (low values indicating relative affluence and high
values deprivation) and divided into seven equal categories (cate-
gories one to six each containing 20 917 areas and category seven
20 918). To enable the contribution of the three components of the
index to be examined separately, each component proportion was
divided into seven categories (as for the deprivation index). For
overcrowding, areas with zero proportions formed the bottom
category, with the remaining areas being divided into six equally
sized groups.
Characteristics of participants
The characteristics of the 3838 children diagnosed with cancer
whose families participated in the study are summarized in
Table 2.
Detailed diagnostic information about 1313 (90%) children with
ALL and 188 (68%) children with other forms of leukaemia was
obtained from MRC treatment trials (Table 2). Confirmatory diag-
nostic data on the 235 children with leukaemia who were not
entered into a trial and the 2102 children with other forms of
cancer were obtained from a variety of sources (see pp. 000 and
000)
There are more boys than girls in each malignancy group. The
largest sex difference was for lymphomas, where 72% of those
diagnosed were male, and the smallest sex difference was for
tumours of the CNS where just over 50% were male (Table 2). The
age-distributions also varied by cancer type. Nearly 60% of the
1461 children with ALL were diagnosed before their 5th birthday,
the median age at diagnosis being 4.4 years. By contrast, around
60% of the children with Hodgkin’s disease were diagnosed after
their 10th birthday, the median age at diagnosis being 11.9 years.
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Table 3 Interviewed controls per interviewed case by control choice
Number of first Number (%) of interviewed
choice controls controls per case
per case
One Two Total
None 23 (0.6) 458 (11.9) 481 (12.6)
One 24 (0.6) 1573 (41.0) 1597 (41.6)
Two – 1760 (45.9) 1760 (45.9)
Total 47 (1.2) 3791 (98.8) 3838 (100.0)
Table 4 Characteristics of the interview
Mothera Fathera
Case Control Case Control
n (%) n (%) n (%) n (%)
Total interviews 3838 (100) 7629 (100) 3679 (100) 7135 (100)
Biological parent
Yes 3818 (99.5) 7600 (99.6) 3596 (97.7) 7010 (98.2)
No 20 (0.5) 29 (0.4) 83 (2.3) 125 (1.9)
Mode of interview
Personal 3772 (98.2) 7550 (99.0) 3153 (85.7) 5143 (72.1)
Surrogate 66 (1.7) 79 (1.0) 526 (14.3) 1992 (27.9)
Marital status
Married/co-habiting 3302 (86.0) 6519 (85.5) 3243 (88.1) 6334 (88.8)
Separated/divorced 303 (7.9) 650 (8.5) 239 (6.5) 454 (6.4)
Other/not known 233 (6.1) 460 (6.0) 197 (5.4) 347 (4.9)
Housing tenure
Owner 2566 (66.1) 5433 (71.2) 2473 (67.2) 5142 (72.1)
Tenant 1156 (30.1) 1992 (26.1) 907 (24.7) 1407 (19.7)
Other/not known 116 (3.0) 204 (2.7) 299 (8.3) 586 (8.2)
Age (years)
< 29 1153 (30.0) 2082 (27.3) 691 (18.8) 1204 (16.9)
30–39 2039 (53.1) 4189 (54.9) 1912 (52.0) 3713 (52.0)
> 40 644 (16.8) 1352 (17.7) 1045 (28.4) 2165 (30.3)
Not known 2 (<0.1) 6 (0.1) 31 (0.9) 53 (0.7)
mean + standard deviation 33.6+6.4 34.0+6.3 36.4+7.2 36.7+7.1
Social classb
I 43 (1.1) 99 (1.3) 253 (6.9) 580 (8.1)
II 497 (12.9) 1291 (16.9) 898 (24.4) 1818 (25.5)
III NM 558 (14.5) 1373 (18.0) 272 (7.4) 585 (8.2)
III M 83 (2.2) 216 (2.8) 887 (24.1) 1777 (24.9)
IV 338 (8.8) 815 (10.7) 406 (11.0) 787 (11.0)
V 107 (2.8) 230 (3.0) 107 (2.9) 167 (2.3)
Armed forces – – 40 (1.1) 62 (0.9)
Not gainfully employed 2212 (57.6) 3605 (47.3) 816 (22.2) 1359 (19.0)
aNot more than two parents per child are included, biological parents taking precedence if both biological and other parents were interviewed. bBased on
occupation at the time of diagnosis.Although 3791 (99%) cases had two interviewed controls,
47 (1%) had only one because a second interview was not secured
before the end of the study (Table 3). Further controls were
selected if those first selected did not participate. Both partici-
pating controls of 1760 (46%) cases were first choices, as was one
of the two participating controls of 1597 (42%) cases; the
remaining 481 (13%) cases had no first choice controls inter-
viewed.
For each child enrolled in the study, up to four parents (biolog-
ical and non-biological) were interviewed, with 121 cases (3%)
and 182 controls (2%) having three or more participating parents.
Overall, the biological mothers of 3818 (99%) cases and 7600
(99%) controls were interviewed. The corresponding proportions
for biological fathers were slightly lower, at 3596 (94%) for cases
and 7010 (92%) for controls.
The characteristics of the parents interviewed are summarized
in Table 4. If both biological and non-biological parents were
interviewed, the data for biological parents are given precedence.
It should be noted that mothers and fathers were not necessarily
living together at the time of the interview.
There are a number of differences between cases and controls
with respect to the characteristics listed in Table 4. For fathers, but
not for mothers, surrogate interviews were twice as common
among controls as among cases: information on about 28% of
control fathers compared to 14% of case fathers being supplied by
someone else (P < 0.05). For both cases and controls, the surro-
gate in over 99% of instances was the child’s mother. The time
interval between diagnosis/pseudo-diagnosis and interview
varied markedly between cases and controls: the medians being
5.8 months and 14.0 months for case and control mothers respec-
tively.
At the time of interview, parents of control children were more
likely than parents of case children to be married (but not neces-
sarily to each other) and to own their own home. At the time of the
child’s diagnosis/pseudo-diagnosis, participating control parents
were, on average, significantly older and of a higher social class
(as assigned on the basis of their own occupation). With respect to
the latter, the largest difference occurred in the proportion who
were not employed at the time of interview: for cases and controls
the proportions being 58% versus 47% and 22% versus 19% for
mothers and fathers respectively (Table 4).
More information about the socio-economic differences
between participating cases and controls is given in Table 5, which
shows the census-derived findings for areal deprivation assigned
on the basis of the child’s address at the time of diagnosis/pseudo-
diagnosis. Overall, the data indicated that participating control
families tended to live in more affluent areas than case families:
there being less unemployment and overcrowding and fewer
homes without access to a car. Interestingly, in agreement with the
findings for social class assigned on the basis of parental occupa-
tion (Table 4), the only significant heterogeneity was for the
proportion unemployed within an area.
That these observations are principally due to participation bias
is supported by the findings presented in Table 6, which compares
the deprivation distributions of interviewed and non-interviewed
first-choice controls. Within this group there are marked differ-
ences between the 5530 who were interviewed and the 2102 who
were not, the latter being far more likely to live in deprived areas
than the former. Importantly, the deprivation distribution of the
7632 first-choice controls was not significantly different from that
of the 3838 cases distribution shown in Table 5.
Discussion
The response from case families was good, with 3838 (87%) of the
4433 eligible cases identified participating. Direct assessment of
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Table 5 Areal deprivation characteristics of interviewed cases and controls
Components of the deprivation index
Deprivation indexa Not gainfully employeda Overcrowdingb Car ownershipb
Cases Controls Cases Controls Cases Controls Cases Controls
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 3838 (100) 7629 (100) 3838 (100) 7629 (100) 3838 (100) 7629 (100) 3838 (100) 7629 (100)
Least deprived 531 (13.8) 1153 (15.1) 502 (13.1) 1041 (13.7) 791 (20.6) 1584 (20.8) 424 (11.1) 716 (9.4)
602 (15.7) 1212 (15.9) 592 (15.4) 1295 (17.0) 621 (16.2) 1227 (16.1) 474 (12.4) 925 (12.1)
589 (15.4) 1160 (15.2) 580 (15.1) 1245 (16.3) 551 (14.4) 1129 (14.8) 551 (14.4) 1057 (13.9)
557 (14.5) 1155 (15.1) 564 (14.7) 1096 (14.4) 491 (12.8) 994 (13.0) 570 (14.9) 1158 (15.2)
504 (13.1) 1037 (13.6) 532 (13.9) 1042 (13.7) 490 (12.9) 980 (12.9) 591 (15.4) 1269 (16.6)
510 (13.3) 993 (13.0) 518 (13.5) 958 (12.6) 455 (11.9) 956 (12.5) 612 (16.0) 1221 (16.0)
Most deprived 545 (14.2) 919 (12.1) 550 (14.3) 952 (12.5) 439 (11.4) 759 (10.0) 616 (16.1) 1283 (16.8)
c2 (P-value) 13.4 (0.04) 15.4 (0.02) 6.9 (0.33) 8.8 (0.19)
aAll UK enumeration districts divided into seven equally sized categories. bThe lowest group contains all zero counts, with the rest divided into six equally sized
categories.
Table 6 Percentage of first choice interviewed and non-interviewed controls
distributed by areal deprivationa
Interviewed
Total Yes No
(n = 7632) (n = 5530) (n = 2102)b
Least deprived 1 14.0 15.9 8.9
2 14.3 16.1 9.8
3 13.7 14.9 10.6
4 14.5 15.2 12.6
5 13.9 13.7 14.7
6 14.3 12.8 18.3
Most deprived 7 15.2 11.4 25.2
asee Methods section for definition; b37 non-interviewed first-choice controls
had missing addresses.the completeness of UKCCS case ascertainment for the years
covered by the study is not straightforward. Ineligible case
children (e.g. those who were born abroad) were not registered in
the UKCCS, and data on all eligible diagnoses were collected in all
regions only for the years 1993 and 1994. Broad comparison with
national data for 1981–1990 suggests, however, that the proactive
case ascertainment methods used in the study were efficient.
Further, the age and sex distributions of the diagnoses included in
the UKCCS are reassuringly similar to those reported for Britain in
the 10-year period 1981–1990 (Parkin et al, 1998).
Participation was not as high for control families as for case
families: parental interviews being secured for 7629 (64%) of
control families compared with 3838 (87%) of case families. The
most important reason for not having an interview was parental
refusal, with 2625 (22%) control parents and 279 (7%) case
parents refusing to participate in the study. In addition to refusals,
5% of the selected control families did not live at the address
supplied by the medical authorities and could not be traced to any
other address. This 5% error rate for addresses is in line with other
reports (RCGP, 1987; Page, 1991; Roberts et al, 1995).
Like all case–control studies that have relied on the recruitment
of individuals for collection of information, the UKCCS findings
have to be carefully evaluated in the light of participation bias.
Participation bias is introduced when those who respond to a study
differ in important respects from those who do not, the conse-
quences in case–control studies invariably being exacerbated by
the fact that cases and controls are not equally affected. The design
of the UKCCS allows the potential effects of participation bias to
be examined in more detail than has been possible in other large-
scale case–control studies of childhood cancer (Kleinerman et al,
1997; McBride et al, 1999): the census linkage enabling the char-
acteristics of areas in which participators lived to be compared
with those of non-participators. The findings from this areal
analysis confirm that the socio-economic differences between
interviewed cases and controls arose because controls categorized
as deprived were less likely to participate than controls who were
more affluent.
POWER FREQUENCY MAGNETIC FIELDS:
DESIGN CONSIDERATIONS
When the UKCCS was initiated, previous studies had suggested
that a possible excess of childhood malignancy, particularly
leukaemia and brain cancer, might be associated with above
average levels of exposure to 50 or 60 Hz electromagnetic fields.
The evidence, however, was inconclusive and further studies
based on appropriate measurements were needed to elucidate the
nature of the relationship between 50 and 60 Hz electromagnetic
fields and childhood malignancy (Advisory Group on Non-
ionising Radiation, 1992).
We describe here the design of the part of the UKCCS relevant
to exposure from 50 Hz magnetic fields (and harmonics below
800 Hz) generated by the distribution and use of electricity.
Residential 50 Hz electric fields were the subject of a pilot study
embedded in the magnetic field study and will form the subject of
a separate paper.
The primary hypothesis, based on the results of the studies
reviewed by the NRPB’s Advisory Group on Non-ionising
Radiation (1992, 1994), was that risk for some childhood malig-
nancies is positively associated with the average magnetic field
level to which a child is exposed in the year before diagnosis. In
particular, average exposures greater than 0.2 microtesla (mT) in
the year before diagnosis would confer greater risk for (i) all
leukaemias; (ii) ALL and (iii) CNS tumours, than average expo-
sure less than 0.1 mT. A further hypothesis is that risk for each of
the above diagnostic categories increases steadily across the range
of dose from less than 0.1 mT to greater than 0.4 mT.
During the course of the UKCCS, but before any analyses were
undertaken, further measurement-based studies had refined the
hypothesis, suggesting that if any risk did exist it was typically
above the 95th percentile of the distribution in the controls of these
studies (Linet et al, 1997; Michaelis et al, 1997; Dockerty et al,
1998; McBride et al, 1999).
Assessment of EMF exposure
For the purposes of this study EMF exposure is defined as the
time-averaged estimate of whole body average magnetic flux
density as derived from the true root-mean-square (RMS)
measurements made in three orthogonal directions. It is a physical
entity for which a ‘gold standard’ measure is theoretically avail-
able, at least for the average field over a year – defined as the
exposure of interest in this study. Personal monitors worn for
extended periods of time would provide an approximation to the
annual average exposure of an individual. Their use in this study
was ruled out on two grounds: firstly, exposure measured by
personal monitor after a diagnosis of malignancy cannot be taken
as a measure of predisease exposure, since the lifestyle will
change; secondly, the cost for the numbers involved would be
excessive.
The measurement protocols in the UKCCS were based on a
pilot study conducted by NRPB. A total of 51 children from the
North East of the Leeds metropolitan area, of a similar age and sex
distribution to all children diagnosed with cancer in the UK, wore
a magnetic field monitor for 48 h. Contemporaneous measures of
50 Hz magnetic flux density were taken in the family room (2 h),
at the centre of up to five rooms in the home (5 min per room), on
the centre of the bed (2 ´ 5 min, separated by 2 h) and at the
bedside (48 h). Measurements were made also in the classroom
(5 ´ 5 min) of those children attending a school or nursery.
On the basis of this pilot study, the 48-h personal exposure of
children was moderately well correlated with combined short-term
measurements made in the bedrooms and family rooms. The corre-
lation was improved when the assessment of exposure included
school measurements and/or residential measurements over 48 h
(r ³ 0.8). It was concluded that household assessment could
provide an adequate measure of an individual’s exposure, provided
that schools were also measured when relevant.
The pilot study indicated that a restricted set of measurements
would classify, with acceptable sensitivity and specificity, an indi-
vidual into the lowest 90% of exposure. For exposures in the top
10%, more extensive measurements would be required, to give a
more precise exposure estimate. Resources, however, were not
available for extensive measurements in the households of all
cases and controls. A two-phase approach was therefore adopted
for the UKCCS.
In the first phase, data were collected for a series of matched
case–control pairs with a single control per case. Information on
EMF exposures was gathered from five different sources (i) speci-
fied measures in the child’s home; (ii) specified measures in
schools or other institutions, such as purpose built nursery schools,
attended by the child; (iii) a questionnaire on electrical appliances
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nearby from an external sources questionnaire (ESQ) and (v)
electricity company databases of historical load data and other
operating characteristics.
In the second phase, more extensive measurements of EMF
levels were made in the home for all children indicated by phase I
to be in the top 10% of exposures, together with the corresponding
matched case or control. The value taken to approximate the 90th
percentile of the phase I measurement was 0.1 mT. Also included
in phase II were individuals living in the proximity of high voltage
overhead lines and underground cables and those with appliances
specified in the phase I questionnaire.
Measurements were made after diagnosis, because of the retro-
spective nature of the study. Retrospective line load data for rele-
vant high voltage lines were obtained from the electricity industry
for the time when measurements were taken and for the year of
interest, i.e. the year before diagnosis or for controls pseudo-
diagnosis. The line load data were used to compute fields for both
the year of interest and for the measurement period. These data
were used to adjust the measurements to generate a historical
exposure estimate for the year of interest.
To prevent identification of high and low measurements by
study technicians, meter readings were not displayed. Information
on the levels of EMFs in individual homes and schools were
provided to study participants on request, but otherwise remained
strictly confidential.
The power of a two-phase approach to exposure
measurement
It is straightforward to evaluate the power of a two-phase design
compared either to a design in which all individuals have only
phase I measurements, or to one in which all individuals have
phase II measurements.
In the simple case where in the whole population the top p% of
phase II exposures have a relative risk of r compared to the
remainder, and the phase I measurement is used to identify q% of
individuals, there are approximately 2q% of case–control pairs on
whom phase II measurements are made.
Figures 4A (r = 1.5) and 4B (r = 2) consider a study of 500
case–control pairs. The three curves give the power to detect a
difference at the 5% significance level for a study in which all
individuals have phase II measurements, a study in which all indi-
viduals have only phase I measurements, and the two-phase design
as described. The benefit of the two-phase approach depends on
the sensitivity and specificity of phase I compared to phase II, but
for a wide range of values there is a major gain in power for rela-
tively little cost, compared with a phase I only study.
Inclusion
All families who had agreed to take part in the UKCCS were
considered for inclusion in the EMF study. Eligibility for inclusion
of both cases and controls was based on the eligibility of the home
address, since exposure was based on household measurements.
Home addresses, of both cases and controls, were eligible if the
child had lived there for 12 months or more before diagnosis or
pseudo-diagnosis and was still living there. ‘Homes’ included
fixed-site caravans, but not ‘mobile’ addresses. If a child was aged
less than 12 months at (pseudo) diagnosis, an address was eligible
if the child had lived there continuously between birth and the time
of (pseudo) diagnosis. No attempt was made to measure previous
homes.
If a case family was ineligible (did not live in current home for
12 months prior to diagnosis) or refused to take part in the EMF
study, no control was invited to participate. Otherwise, the family
of the matched control with the lower identification number was
approached. If this first control family was ineligible or refused to
participate, then the second control was approached and incorpo-
rated in Phase I, if eligible. If both controls were ineligible or
refused to participate, the exposure of the case was not measured.
Due to delays in starting the EMF study, there was an interval of
variable length between the date of (pseudo) diagnosis, and the
date of the Phase I measurements. This affected the number of
case–control pairs on whom measurements were available.
Schools were eligible if the child had attended them for 15 or
more hours per week during the winter (October to March) imme-
diately preceding (i.e. not including) the date of (pseudo) diag-
nosis. If the child attended more than one school in this period, the
school in which the longest time was spent, in terms of the total
number of hours, was chosen. ‘School’ included pre-schools in
established, purpose-built buildings.
Instrumentation
Commercially available Emdex II magnetic field meters (Enertech
Consultants Ltd, USA) were used to measure resultant magnetic
fields in the broadband frequency range 40–800 Hz. The meters
incorporate three orthogonal sensing coils to measure true RMS
magnetic flux density over the range 0.01–300 mT. The measure-
ment resolution is 0.01 mT and the overall accuracy within the
range 0.01–10 mT is ± 10% ± 0.005 mT. Computer memory inside
the meter allowed data logging over extended periods. For short-
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Figure 4 Comparison of three sampling strategies: n = 500, P = proportion
of controls exposed (phase II measure), q = proportion classified as exposed
by the surrogate (phase I measure)term measurements, of two hours or less, magnetic flux density
was recorded at sampling intervals of 1.5 and 3 s in the phase I and
phase II assessments respectively. The sampling interval was
adjusted to 10 s for longer measurements.
The instruments were calibrated in a Helmholtz coil facility
which had an uncertainty of ±2.5%, traceable to national stan-
dards. Instruments were calibrated before issue to the study techni-
cians and at intervals during the course of the study.
A check source generating a magnetic flux density of about
5 mT was developed to assess instrument integrity prior to and
following each set of site measurements. General faults or the
failure of any single sensing coil could be detected. Check source
records were downloaded with measurement data following each
site visit.
A subset of phase II case–control assessments also recorded
electric field strength for a pilot study, using the same meters fitted
with an external sensor. Based on laboratory tests the attenuation
of magnetic flux density by the sensor was about 4%.
Phase I residential measurements
The phase I residential measurements comprised in order: (i) three
3-min spot measurements taken in the centre of the child’s
bedroom, at the centre of the child’s bed, and on the centre of the
child’s pillow; (ii) a 90-min measurement taken in the centre of the
main family room; (iii) a repeat of the three spot measurements
after the 90-min measurement.
Apart from the readings made on the bed, all these measure-
ments were made with the instruments placed at a height of 1 m
from the floor in a polypropylene stand and at least 1 m from any
operating appliances.
The aim was to measure the homes of the case and of the corre-
sponding control less than 4 months apart. If the period between
measurements was greater than this, the earlier measurement was
repeated. If a household measurement was repeated, the earlier
reading was retained for study of repeated measurements.
During the phase I household visits, questions were asked about
the time that the child spent in bed and at school, which were used
in the calculation of time-weighted exposures.
Phase II residential measurements
The matched case–control pair of phase II measurements were
made as close as possible to each other and within a 4-week
period.
Where the phase I questionnaire identified that a child’s expo-
sure might include exposure from a night storage heater or under-
floor heating in the bedroom, then the phase II measurements
covered a period during which the particular appliance was in use,
typically during the winter months.
Phase II measurements took place during a period agreed with
the appropriate electricity company as ‘a period of typical
operation of the local distribution system’. The measurements
comprised: (i) four 3-min spot measurements taken at the centre of
the family room, at the bedside position to be used for the 48-h
measurement, at the centre of the child’s bed and at the centre of
the pillow; (ii) a 48-h measurement taken by the side of the middle
of the child’s bed; (iii) a repeat of the four spot measurements after
the 48-h measurement.
Again, apart from the readings made on the child’s bed, all of
these measurements were made with the instruments placed at a
height of 1 m from the floor in a polypropylene stand and at least
1 m from any operating appliances. Tamper-proof holders were used
for the extended 48-h measurements by the side of the child’s bed.
Measurement in schools
School measurements took place when the heating systems were
operating normally, which in England & Wales was taken to be the
months October to March inclusive. There were two measurement
schemes. The first was used when the child occupied a single
classroom for the majority of the time spent at school during the
relevant winter period, typically in primary schools. This scheme
consisted of five 2-min spot measurements near the centre and four
corners of this single room. When many classrooms were used,
typically in secondary schools, spot measurements were made in
up to five of the rooms most frequently used during the relevant
winter period. In each of these rooms, a single measurement was
made near the room centre, the measurement time totalling 10 min
and the measurements in the different rooms being of equal dura-
tion. All measurements were made at a height of 1 m from the
floor and at least 1 m from any operating mains appliance.
Appliances
During the phase I visit, questions were asked on use of underfloor
heating and night-storage heating in the house including the child’s
bedroom, with observation of position and type. These appliances
were chosen firstly on the basis that the position of the appliance
and child were well defined over the period of use and secondly
that the appliance field contribution over the likely period of use
could increase mean exposure from less than 0.1 mT to greater than
0.2 mT.
Where such an appliance was identified and used, the
case–control pair qualified for the phase II assessment; this was
carried out when the night-storage heater/under-floor heating was
operating normally. Using appropriate periods of the 48-h
measurement, specific exposure calculations were undertaken for
these appliances, their contribution considered to be material only
during the winter night-time. Use of an electric blanket was also
ascertained; if a blanket was used and was available, permission
was asked to send it to NRPB for detailed magnetic flux density
measurements to assess the exposure.
In phase I exposure estimates, computed appliance field over
the relevant period of use was combined with the measured back-
ground field by means of root sum of squares (RSS). Algorithms
for computing appliance field were derived from investigations in
the laboratories of NRPB and electrical testing houses, corrobo-
rated by evidence from UKCCS measurements. The same
approach was adopted for phase II where there was no operating
heating appliance during the overnight bedroom measurements.
Further questions were asked on other specific household
sources of EMF (hairdryers, microwave ovens, electricity meters
and central heating systems) to assess potential misclassification.
This is to be the subject of secondary analyses.
External sources
An External Sources Questionnaire (ESQ) was completed for each
EMF study participant to identify important sources of electricity
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National Grid Company (NGC) and the Regional Electricity
Companies (RECs) for England & Wales, and Scottish Power and
Scottish Hydro Electric in Scotland, the specific purposes of the
questionnaire were as follows: to identify high voltage lines and/or
underground cables that had the potential to produce annual
average field levels above 0.1 mT at the home and/or school; to
obtain load and other circuit information to enable reconstruction
of historical exposure; to check that the electricity distribution
system was operating typically at the time of measurement; to
identify substations and particular types of low voltage circuits
that were near to the location of interest. The ESQs, blinded with
respect to case–control status, were evaluated by NRPB.
Entry into phase II, on the basis of the ESQ was determined by
the following criteria for England & Wales: (i) an NGC line within
400 m or underground cable located within 100 m of the home;
(ii) a REC line of 66 kV or above, located within distances up to
200 m from a home; (iii) a REC line of 11–33 kV located within
distances up to 80 m from a home; (iv) an operating substation or
a phase-separated underground cable of 33 kV or above within
20 m; (v) a 3-phase 415 V distribution circuit located within 2 m
of the home; (vi) atypical conditions of distribution circuits. In
Scotland, equivalent criteria based on line voltages were used.
The threshold distances used to determine the relevant phase II
circuits were based on design rating and therefore judged to be
conservative. Typical loads on a REC line were found to be less
than 20% of the circuit rating. Analysis of load data from a sample
of NGC circuits during a winter period had indicated previously
that 50% and 95% of the circuits had respective average loads of
less than 30% and 50% of their rating (D Renew, NGC, personal
communication).
External sources questionnaires were issued also for the non-
measured participants in the main study. These were interviewed
cases and controls who were either ineligible for EMF measure-
ments (because they had moved house either during or since the
time of interest) or who were eligible but had declined to partici-
pate in this part of the study. To investigate the possible effects of
refusal bias, ESQs were also issued for a random sample of one
thousand (approximately two-thirds) of the first-choice controls
who had refused to take part in the full study.
Historical exposure computations
Line load data were requested for all overhead lines whose volt-
ages were 66 kV and above within certain threshold distances
from the location of interest. For REC lines, threshold distances
were used to identify homes and schools where the annual
average magnetic field could exceed 0.15 mT. The distances were
based on maximum loads as defined by the circuit rating, and
relative phasing information. In practice, loads were well below
the circuit rating as described in the previous section. For trans-
mission lines, the annual load current or half of the average circuit
rating and other detailed operational information, were used to
define line-specific threshold distances. These distances were
established for annual average magnetic fields of 0.1 mT. On a
similar basis, load data were also requested for phase-separated
underground cables of 66 kV and above, located within 20 m of
the property.
National Grid Company’s EM2D program was used to compute
magnetic field levels. The program, evaluated by NRPB for the
purposes of the study, was used to calculate the RMS magnetic
flux density averaged over the measurement period and over the
year of interest, which were used in the exposure algorithm. To set
up a model, circuit parameters including line/tower type,
conductor height above ground, distance, measurement height,
phasing of circuits and current direction, were used as input data.
A three-dimensional (3D) version of the program was used in
some circumstances.
Load data contemporaneous with the period of measurement
and the year of interest were requested. These were usually
provided as a continuous series of load current/power values for
each circuit, sampled at 1-min intervals for phase I, and at half-
hour intervals for the year of interest. To allow for the temporal
characteristics of line loading (Kaune et al, 1998), the values were
sorted into separate date–time files to cover the appropriate
periods of the year of interest. Where companies could not provide
data for the relevant period, data for the closest alternative period
were requested. If load data were not available, engineers were
requested to provide best estimates based on available company
records.
In a previous study carried out by NGC (Swanson, 1995), good
agreement was found between instantaneous measured magnetic
fields and the computed values. Using a similar computational
approach to that used in the UKCCS, the error was estimated to be
± 6% at 0.1 mT. in the UKCCS, the typical overall uncertainty was
estimated to be ± 20%, and checks with measurements implied
worse case uncertainty of approximately ± 40% within 50 m of a
power line, falling to ± 30% at 100 m. The additional computa-
tional error was mainly due to uncertain ESQ information, particu-
larly the location and elevation data, and departures from the 2D
modelling assumption.
In the UKCCS the year of interest exposure adjustment was
made for all cases and controls where homes and schools attended
met the criteria outlined above and for which load data were
received. The calculation was based on a root sum/difference of
squares method. A residual component, representing a constant
‘local source’ was derived by subtracting the contemporaneous
calculated field from the measurement, and this RSS was
combined with the year of interest calculated field. There were
instances where the calculated field was greater than the measured
field and these were ascribed to the inaccuracies in the parameters
for the computational model, which have been described above.
A comprehensive review was carried out of the modelling
parameters used. Where calculated fields remained greater than
the contemporaneous measured fields, the year of interest expo-
sure was determined by adjusting the measured field by the ratio
of the calculated fields for the two periods.
Algorithm for combining measurements
On the basis of heating appliances contributing to exposure only
during winter months, average exposure in the year preceding
(pseudo) diagnosis was estimated using the following algorithm:
Average exposure = W1.(Bed: Winter Exposure) + W2.
(Bed: Summer Exposure) in year of interest 
+W3.(School Exposure) + W4. (Home Non-Bed Exposure)
The weights (W1–W4, SWi = 1) were individually calculated for
each child to reflect the time spent in bed and in school, as
recorded in the study questionnaire. Where any of the information
needed to compute the weights was missing, average, age-related
values were used.
1084 UK Childhood Cancer Study Investigators
British Journal of Cancer (2000) 82(5), 1073–1102 © 2000 Cancer Research CampaignIn phase I, bed and home non-bed exposures were estimated
from measurements in appropriate locations covered by a 2-h
period. Bed exposure was estimated from bedroom spot measure-
ments and the average of the 90-min family room measurement
was used as an estimate of exposure for time not spent in bed or at
school. In phase II, bed exposure and home non-bed exposure
were estimated from the 48-h measurement and the phase I family
room measurement. School exposure was common to both phase I
and phase II.
Where necessary, to allow for changes in line loading and circuit
configuration between the year of interest and the time of measure-
ment, home and school measurements were adjusted to reflect the
situation in the year before (pseudo) diagnosis. For bed-winter
exposure, measurements were combined with appliance fields
where appropriate. For bed-summer exposure, measurements were
unadjusted.
Characteristics of the phase I and phase II measures
The validity of the measures used in this study has been evaluated
against the use of personal monitors in a substudy carried out by
NRPB. This ‘gold standard’ validation study, estimated individual
exposure by the use of personal monitors in three separate weeks
during the year on a sample of 100 healthy children. It will be
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Table 7 Correlation between different elements of phase I and phase II, for log-transformed data (n = 1185)
Phase I Phase II
AREPI BedPI Non-bedPI ETPII BedPII Non-bedPII
AREPI 1
BedPI 0.95 1
Non-bedPI 0.87 0.73 1
ETPII 0.75 0.73 0.74 1
BedPII 0.75 0.75 0.70 0.89 1
Non-bedPII 0.72 0.64 0.80 0.82 0.81 1
AREPI: Phase I estimate of average residential exposure (= BedPI and Non-bedPI weighted by questionnaire data). BedPI: Average of the six spot
measurements (two each in bed centre, pillow, bedroom centre) made in the bedroom during phase I. Non-bedPI: 90-min measurement made in family room
during phase I. ETPII: 48-h extended time measurement made beside child’s bed in phase II. BedPII: Average of the six spot measurements (two each in bed
centre, pillow, 48-h measurement position) made in bedroom during phase II. Non-bedPII: Average of the two spot measurements made in family room during
phase II.reported elsewhere. The sample was chosen to have 50 children
from 50 households with phase I measurements less than 0.1 mT,
and 50 with phase I measurements greater than 0.1 mT.
Phase I measurements
The distribution of phase I measurements based on nearly 5000
measurements to the end of the study is displayed for annual
average exposure, on a log scale, in Figure 5. The distribution is
strikingly close to log normal, with a geometric mean of 0.032 mT,
and a retransformed standard deviation of 0.031 mT. The mean
phase I exposure level falls between the geometric mean levels
of 0.029 and 0.037 mT, published previously for UK homes
(Merchant et al, 1994a, 1994b; Preece et al, 1996; Swanson and
Kaune, 1999). The residential and school components of the total
exposure have a similar distribution. There was some evidence of
diurnal and seasonal variation in phase I measurements, reflecting
the known daily and seasonal changes in the use of electricity.
Table 7 indicates the correlation between the different components
of the phase I measurements, and with the overall residential expo-
sure from phase I. All correlations are given for data on a log scale.
Table 8 gives the correlation between phase I measurements
taken at different times in the same home, by the time interval
between the two measurements. The data include a sample taken
in Scotland to examine replication of phase I measurements. The
correlation shows no decrease with time, for intervals of up to 4
years between measurements.
These phase I Tables, and those for phase II, are based on all
measurements taken. This includes measurements on individuals
who will not be included in the final analysis; for example, those
for whom the matching case or control was not measured, or those
found to be ineligible for the study as a whole.
Phase II measurements
By the end of the study, nearly 1200 phase II measurements were
made. Seasonal variation similar to that in the phase I data was
observed.
Table 7 gives the correlation between the different component
measures in phase II and with an overall phase II household
measure based on the 48-h bedside measurement, together with the
corresponding phase I measures, all on a logarithmic scale. Table 9
gives the correlations between phase I and phase II estimates of
total residential exposure, for different intervals of time separating
them. The correlation is only weakly related to the length of the
interval. The correlations are higher in Table 9 than in Table 8,
which reflects the greater variance among individuals on whom
phase II measurements are taken. The standard deviation of the
differences between the two measurements (on a logarithmic
scale) is almost identical in the two situations, about 0.8.
The relationship between the two measurements can also be
expressed in terms of sensitivity and specificity as mentioned
earlier. Table 10 cross-tabulates the two measures in terms of the
cut-off for phase II, i.e. 0.1 mT, and the level at which risk is
hypothesized to be elevated, i.e. 0.2 mT. The individuals in Table
10 with phase I measurements less than 0.1 mT represent only 15%
of all such individuals, whereas all those with phase I measure-
ments greater than 0.1 mT should have phase II measurements and
thus be included in this Table. With this correction, the sensitivity
and specificity of phase I with respect to phase II are 0.80 and 0.98
respectively. As can be seen from Figure 4A and B, these values
suggest that the two-phase approach will lead to a substantial
increase in power and be close to that achieved by taking phase II
measurements on everyone.
Analysis
The diagnostic categories on which the primary analysis will focus
are defined by the full study hypotheses, namely all leukaemias,
ALL, CNS tumours and others.
The data relating to EMF exposure are classified in three
groups.
In Group A, complete data (i.e. residential and school measure-
ments where necessary and external source data) are available for
both members of each case–control pair. It includes approximately
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Table 8 Correlation between estimates of average residential exposure
(AREPI) for repeat phase I measurements, for log-transformed data (median
time between measurements = 1.41 years)
Time between measurements Correlation Sample size
<6 months 0.39 3
6<12 months 0.58 68
12<18 months 0.72 64
18<24 months 0.59 50
24<30 months 0.69 61
30<36 months 0.80 11
36<42 months 0.78 47
42<48 months 0.96 3
48<54 months 0.73 5
Table 9 Correlation between phase I (AREPI) and phase II (ETPII)
estimates of average residential exposure by time between measurements,
for log-transformed data
Time between measurements Correlation Sample size
All measurements 0.75 1185
≤ 1 year 0.76 607
> 1 and < 2 years 0.75 396
³ 2 years 0.66 182
Table 10 Cross-tabulation of phase I (AREPI) and phase II (ETPII)
estimates of average residential exposure with percentage figures in brackets
(n = 1185)
ETPII < 0.1 mT 0.1 mT ≤ ETPII < 0.2 mT ETPII ³ 0.2 mT
AREPI < 0.1 mT 835 27 2
(70.5%) (2.3%) (0.2%)
0.1 mT ≤ AREPI < 0.2 mT 133 75 17
(11.2%) (6.3%) (1.4%)
AREPI ³ 0.2 mT2 9 3 1 3 6
(2.4%) (2.6%) (3.0%)
Table 11 Number of eligible case–control pairs by diagnostic category
Category No. of pairs
Acute lymphoblastic leukaemia 906
Other leukaemias 167
Non-Hodgkin’s lymphoma 165
Hodgkin’s disease 74
Central nervous system tumours 387
Other malignancy 527
Total 222660% of all interviewed cases and a corresponding number of
controls, not all which were necessarily first choice.
In Group B, EMF measurements are not available for each
member of a pair, but external source data are available both for
the case and the first-choice control.
In Group C, external source data are available for a random
sample of 1000 of the 1582 first-choice controls for the cases with
measurements in Group A that did not have full measurements and
may or may not have had family interviews.
The primary analyses have been based on the case–control pairs
with full EMF data available (Group A). The numbers of such
case–control pairs for each main diagnostic category are given in
Table 11. Approximately 20% of case–control pairs had phase II
measurements. Annual average exposures based on the phase II
measurements were used in the analysis when available on both a
case and the corresponding control. If a phase II measurement was
available for only one of a case–control pair, then phase I measure-
ments were used for both. For the remaining 80% of case–control
pairs, the annual average exposure based on the phase I measure-
ment was used.
We will use as the exposure of interest the arithmetic average
exposure in the year preceding (pseudo) diagnosis. Analyses will
focus on comparisons between high (greater than 0.2 mT) and low
(less than 0.1 mT) exposures and on a linear relationship between
risk and dose.
RADON AND TERRESTRIAL GAMMA RADIATION
Environmental exposure to low-level ionizing radiation is princi-
pally from radon and its decay products, cosmic rays, terrestrial
gamma rays and radionuclides in food and drink (Hughes and
O’Riordan, 1988). The ability of high linear-energy transfer alpha
particles present in the terrestrial environment to cause cell
damage, potentially leading to malignancy, has prompted partic-
ular interest. Radon (including its decay products) is established as
a possible cause of lung cancer (BEIR IV, 1988) but other health
effects have been suggested such as leukaemia in both adults and
children (Henshaw et al, 1990).
Radon gas tends to become trapped within houses and may
prove to be a source of a significant dose of alpha radiation.
Representative measurements of the amount of radon in homes
have been made on a national scale by the NRPB (Wrixon et al,
1988). Radon levels, however, vary between adjacent houses and
direct measurements rather than geographic generalizations are
essential to determine the levels to which individuals have been
exposed. Attempts have, therefore, been made to measure the
levels of radon in the present and past homes of all the children
participating in the UKCCS.
Absorbed dose rates from external gamma sources are about
twice as great indoors as outdoors in the UK. The mean indoor
absorbed dose rate of 60 nGy per hour, which translates into an
effective dose in dwellings of 280 mSvy–1, is lower than in most
countries studied (United Nations Scientific Committee on the
Effects of Atomic Radiation, 1993) but is based on survey data
from some years ago and a sample size of 2300 households.
External gamma radiation indoors has also been measured and this
survey will materially add to knowledge of UK gamma distribu-
tion generally as well as specifically investigating any association
with childhood cancers.
Materials and methods
As part of the study, a face-to-face interview was conducted with
each child’s parents. A full residential history for the child was
collected and all UK addresses lived in by the child, from birth to
diagnosis, for 6 months or more were targeted for measurement of
both radon gas and terrestrial gamma radiation. A written request
to participate, in what was described as a ‘Child Health Survey’,
was made to the occupants of each past residence, with a follow-up
letter if there was no response to the first. Following agreement,
detectors were sent to each household with instructions to place
one in the main bedroom and one in the main living area. Two
passive radon detectors, provided by the NRPB, were used to
measure the concentration of radon gas (Wrixon et al, 1988) and
two passive detectors were used to measure the terrestrial gamma
radiation. After 6 months had elapsed, a letter was sent recalling
the detectors, which were returned to the NRPB in pre-paid
envelopes for processing and measurement of the cumulative
radon exposure indicated by the alpha-particle tracks made by the
radon decay products. We describe here the methods by which
exposure to radon was assessed, using the data obtained for the
control children to illustrate it. Details of the less complex assess-
ment of exposure to terrestrial gamma radiation will be reported
later with the results.
Measurement of radon exposure
Table 12 shows the number of control households approached, the
number that participated for which measurement was obtained and
the fate of the detectors that were sent out. Although detectors
were intended to be in place for 6 months, the period over which
measurements were actually made varied. The analyses were
restricted to those measurements from detectors which had been in
place for between 5 and 7 months within a household for both
living room and bedroom. After excluding faulty detectors and
other missing information, there were 11 356 detector measure-
ments available for 5678 control households (44.5% of the initial
total).
Outdoor correction
The modelling of seasonal correction factors assumes the
frequency distribution of radon concentrations in households is
log-normal. Previous research, based on the NRPB data, suggested
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Table 12 Summary of measurements made in control houses
Category Numbers %
Households
Potential householdsa 12 757 100.0
Households which refused detectors 5774 45.3
Households with detectors sent 6983 54.7
Total measured households 5678 44.5
Detectors
Despatched 13 966 100.0
Total returned by household 11 899 85.2
No measurement given 66 0.5
Faulty 164 1.2
Incorrect dates of placement 8 < 0.1
Total valid detectors 11 661 83.5
Not in place for 5–7 months 144 1.0
Only one room measured 161 1.2
Total detectors analysed 11 356 81.3
aHouseholds lived in for more than six months by the child.the overall distribution followed a log-normal distribution more
closely when each household measurement had 4 Bq m–3
subtracted (Gunby et al, 1993). This was informally termed an
‘outdoor correction’ factor as limited surveys of radon indicated
outdoor levels to be low, around 4 Bq m–3. The assumption driving
the ‘outdoor correction’ was tested on the UKCCS data prior to
correction for season.
Seasonality
The aim of the radon survey was to measure average concentra-
tion of radon gas over a year. Radon becomes trapped within a
building, as it is drawn up from the underlying rock and released
gradually from the house through windows, doors and other
ventilation. Different levels of heating and ventilation through-
out the course of a year cause radon levels to fluctuate by season
(Pinel et al, 1995). Due to the constraints of time placed on an
epidemiological study, it is usual for radon detectors to be in
place for approximately 6 months, therefore, a multiplicative
factor is required to correct for seasonal variation. The NRPB
have derived corrections from their own national survey of
houses (Wrixon et al, 1988). These, however, are not based on
the same sampling frame as the UKCCS data which is for houses
in which there are young children. For this reason, seasonal
correction factors were derived from the UKCCS sample,
extending standard methodology by testing the validity of
regional-specific factors. In broad terms, the methodology of
Pinel et al (1995) uses the set of household measurements to
calculate the mean concentration of radon for each month of the
year; these monthly values are then used to derive seasonal
correction factors.
The measurement, mi for each household i, obtained by the
NRPB was in kilobequerels per cubic-metre hours (integrated
exposure). This converts to a mean concentration of
where pi is the number of days the instruments were in place.
Measurements often differ substantially between living room and
bedroom, due to living rooms generally being closer to the ground
floor; the source of radon. The NRPB surveyed times spent within
different parts of the house (Wrixon et al, 1988) which suggested
an average person spent 55% of their time in home in the bedroom
and 45% in the other living areas. Previous UK studies (Darby et
al, 1998) have used this division to allocate weighted average
concentrations for each house, and this was used to calculate mi in
preference to a simple average.
The mean concentration of radon for each month was calculated
as
for all months, j = 1, …, 12 with the middle day of the measure-
ment period for dwelling i falling between the middle of the month
j21 and the middle of the month j. This ensures the measurement
duration is symmetrical around the month it is assigned. Nj is the
number of measurements in the jth month. The most appropriate
locational measure for a log-normal distribution is the geometric
mean, which was used throughout the modelling procedures to
estimate the average radon concentration. The geometric mean
concentration for each month was calculated as dj = exp(xj).
A sine–cosine curve was fitted to the geometric mean monthly
concentrations. The derived seasonal variation allows a correction
factor to be calculation (Pinel et al, 1995).
Seasonality correction by region
Seasonality is partly a function of the magnitude of variation in
local climatic conditions, and the severity and lengths of seasons
differ substantially across Great Britain. Therefore, it seems
reasonable that seasonality in levels of radon concentration may
vary across the UKCCS study regions, a hypothesis tested
formally using these data. Mean monthly radon concentrations
were calculated separately for households within each UKCCS
study region, and these estimates were used with an indicator vari-
able for the study region as a formal test of whether estimated
coefficients were significantly different between regions.
Statistically significant differences would support use of region-
specific seasonal correction factors.
Results
The frequency distribution of the radon concentration by house-
hold (regionally adjusted for season) is log-normally distributed,
as would be expected for data of this type (Figure 6). Prior to
seasonal correction the annual average radon concentration (arith-
metic mean) for all households was 21.32 Bq m–3, ranging
between 0.36 and 1192.97 Bq m–3 (Table 13). Regional annual
averages, prior to seasonal correction, ranged from 16.36 Bq m–3
in Scotland to 34.43 Bq m–3 in the South West study region.
Household measurements of radon concentration, prior to
‘outdoor correction’, closely follow a log-normal distribution and
there was no improvement in fit after the correction (data not
shown).
Seasonal correction factors for a detector in place for 6 months
exactly are shown in Table 14. The measure of the proportion of
variation in the data explained by the model R2, are reported. All
models fit the data with between 0.50 (South West) and 0.79
(Trent) of the variation explained by the seasonal curve. The
model which used mean monthly radon concentrations calculated
for each region separately, with an indicator variable for region,
gave a significantly better fit than a model without the term
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Figure 6 Frequency distribution of annual average radon concentration in
houses of controls (regionally adjusted for season)(Table 15). This provides confirmation that the calculation of
seasonality correction factors on a region-specific basis is appro-
priate.
Table 16 shows the annual average household concentration of
radon for each study region after applying the region-specific
seasonality correction factors. The South West study region
continued to measure the highest average levels, 34.47 Bq m–3 and
Scotland the lowest, 16.74 Bq m–3. Table 17 divides the house-
holds into categories, the highest category containing 0.7% of all
measured control households, being that equal to or above the
‘action level’ of 200 Bq m–3, determined by the NRPB as the level
above which remedial work to a house should be carried out.
Discussion
The UKCCS has collected radon gas measurements for a large
number of residences, which are linked to information about the
families living there. These measurements will provide the basis
for an epidemiological analysis of the association between radon
in homes and the incidence of childhood cancer. The study for
which these measurements were made involved a population-
based sample of children with cancer and two controls. The homes
for the selected control children were representative of homes in
the general population containing children of the same age and sex
as the affected children. Satisfactory measurements were,
however, obtained for less than half the target number and the
effect of non-compliance on the risk estimates will have to be
taken into account in studies of the association of childhood cancer
with radon exposure.
The levels of radon gas in homes were generally low, with 74%
of households having annual average radon concentrations of less
than 25 Bq m–3. The seasonally adjusted (arithmetic) average
annual concentration for the entire study, 24.7 Bq m–3, was higher
than the NRPB estimates for UK housing of 20.5 Bq m–3 (Wrixon
et al, 1988). This may reflect the differences between the sampling
frames, the present one being houses with children, and between
the UK housing stock at the two periods. The low proportion of
households exceeding the government ‘Action Level’, 0.7% above
200 Bq m–3, is consistent with, but higher than, the national
average of 0.5% (Kendall et al, 1988).
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Table 13 Annual average concentrations of radon in control houses in each study region (not seasonally adjusted)
Annual household radon concentration (Bq m–3)
UKCCS study region n Arith meana s.d. Geo meanb s.d.c Minimum Maximum
Central/South Walesd 538 26.96 39.60 18.84 2.12 2.22 542.08
East Anglia 467 21.29 15.94 17.16 1.92 2.38 118.89
North East 745 23.62 31.65 16.19 2.21 2.34 340.19
North West 772 17.72 26.74 12.12 2.15 1.32 354.48
Scotland 860 16.36 36.09 10.95 2.19 0.36 886.70
South East 429 22.25 20.49 16.22 2.21 1.84 165.34
South Midlands 573 30.52 63.85 18.97 2.36 1.19 1192.97
South West 731 34.43 66.36 19.70 2.60 0.91 1179.20
Trent 563 28.64 29.48 20.40 2.20 1.93 234.68
All regions 5678 24.32 30.42 15.95 2.30 0.36 1192.97
aArithmetic mean. bGeometric mean. cExponential of the geometric standard deviation. dThe South Wales Study region was combined with Central.
Table 14 Seasonal correction factors and model fit for a 6-month placement of the detector derived from control houses
Correction factor for month of placement
UKCCS study region R2 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Central/South Wales 0.77 1.15 1.19 1.16 1.09 1.00 0.93 0.88 0.86 0.88 0.92 1.00 1.08
East Anglia 0.55 1.01 1.08 1.14 1.16 1.13 1.07 0.99 0.93 0.89 0.88 0.90 0.94
North East 0.57 1.05 1.13 1.18 1.17 1.11 1.03 0.95 0.89 0.87 0.87 0.91 0.97
North West 0.72 1.07 1.12 1.14 1.12 1.06 1.00 0.94 0.90 0.89 0.91 0.94 1.00
Scotland 0.50 1.04 1.13 1.19 1.19 1.14 1.05 0.96 0.90 0.86 0.86 0.89 0.96
South East 0.55 1.20 1.32 1.34 1.24 1.09 0.95 0.86 0.80 0.80 0.84 0.92 1.05
South Midlands 0.53 0.96 1.04 1.12 1.17 1.18 1.13 1.05 0.97 0.90 0.87 0.87 0.90
South West 0.50 0.98 1.01 1.03 1.04 1.05 1.04 1.02 0.99 0.97 0.96 0.96 0.97
Trent 0.79 1.51 1.43 1.23 1.02 0.87 0.78 0.75 0.77 0.84 0.98 1.18 1.40
All regions 0.51 1.04 1.08 1.09 1.08 1.05 1.01 0.97 0.93 0.92 0.93 0.95 0.99
Table 15 Model fit and the effect of region on the seasonal model for
controls
Regions Coefficient (95% CI)a
North West (baseline) 0 (–)
North East 6.22 (2.54–9.89)
South West 8.06 (4.39–11.73)
Trent 7.69 (4.02–11.36)
Central and South Wales 6.89 (3.22–10.56)
East Anglia 6.33 (2.66–10.00)
South Midlands 6.96 (3.29–10.63)
South East 5.36 (1.69–9.03)
Scotland 0.64 (–3.03–4.31)
Likelihood ratio c2 (P-value)b 39.55 (< 0.001)
Ra 0.38
aSignificant at P < 0.05 in bold. bTest against the seasonal model only.
cCompared with a value of 0.11 without the regional correctionIn contrast to our findings, previous research based on NRPB
data suggested that the overall distribution of radon followed a
log-normal distribution more closely when the entire data set had
4 Bq m–3 removed (Gunby et al, 1993). This was informally
termed an ‘outdoor correction’ factor as limited surveys of radon
indicated outdoor levels to be low: around 4 Bq m–3.
Unfortunately, exact comparisons with our data could not be made
as the results presented by Gunby et al (1993) were truncated, and
omitted the first 5% of the data. The occupancy patterns used for
the allocation of a weighted average household radon level were
from a national study based on persons of all ages. Two small
studies carried out for the UKCCS on children do not contradict
these findings.
The data were examined regionally because of concern that
seasonal patterns in radon concentrations may vary across the
country because of differences in climate, housing type and behav-
iour. Examination of the data confirmed the fact that seasonal
correction factors would be more appropriately calculated on a
region-specific basis. The study regions were defined a priori for
the purposes of data collection, were geographically contiguous
and contained approximately similar numbers of persons. To
check that the hypothesis can be supported by the data, the
sine–cosine seasonality curve was modelled for region-specific
mean radon concentrations. The model fit was improved after
adding a variable for the region, as would be expected after inspec-
tion of the seasonal correction factors, with Scotland and the North
West being significantly different from the other study regions.
The data set described here documents an important profile of
radon gas concentrations in a specific section of UK housing;
namely, that inhabited by children. This is the largest data set of
measurements aimed not at identifying areas affected by high
levels of radon (Miles et al, 1996) but at characterizing a popula-
tion-based sample of the population. The appropriate allowance
for geographical differences in seasonality provides a basis for
epidemiological investigations into the association between radon
and childhood cancer.
DIAGNOSTIC REVIEW AND CLASSIFICATION OF
SOLID TUMOURS
For the purposes of data analysis cases must be classified
according to diagnosis into a manageable number of groups.
Descriptive epidemiological data on cancer are often presented in
terms of categories in the neoplasms chapter of the International
Classification of Diseases (WHO, 1992). This system is based on
anatomical site and while this is broadly satisfactory for adult
onset cancers, where over 85% of non-haematological malignan-
cies are carcinomas (Berg, 1996) this is not satisfactory for paedi-
atric cancers which form a specialized group of rare neoplasms
with adult-type carcinomas being exceedingly uncommon
(Stocker and Askin, 1998). Paediatric cancer data are more satis-
factorily grouped, utilizing the International Classification of
Diseases for Oncology (ICD-O) (WHO, 1990). In this system
tumours are described in terms of morphology and topography.
The second edition of ICD-O (ICD-O2) includes more than 1600
morphology codes (M codes) and more than 300 topography codes
(T codes), consequently hundreds of thousands of M and T code
combinations are possible. A system that groups combinations of
M and T codes together is, therefore, required to provide a smaller
number of diagnostic categories for practical purposes. This report
describes the diagnostic review of non-leukaemia cases and the
classification scheme based on ICD-O2 which has been employed
to group cases for analysing data to test the UKCCS hypotheses.
The review process
All but the leukaemia cases were eligible for diagnostic review
regardless of whether the children’s parents were subsequently
interviewed for the study. Registration details were obtained prin-
cipally from the UKCCSG Data Centre. During the period of the
study more than 80% of all incident cases of cancer in children in
England, Scotland and Wales were referred for initial treatment to
UKCCSG paediatric oncology member centres. Registration
details for remaining cases were obtained from the UKCCS
regional epidemiology centres or, for a small number of cases,
through the National Register of Childhood Cancers. UKCCS
registration numbers for each eligible case were obtained from the
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Table 16 Annual average concentrations of radon in control houses in each study region (seasonally adjusted by region)
Annual household radon concentration (Bq m–3)
UKCCS study region Number Arith meana s.d. Geo meanb s.d.c Minimum
Central/South Wales 538 27.70 40.74 19.38 2.12 2.22
East Anglia 467 22.18 16.62 17.82 1.93 2.54
North East 745 24.40 31.76 16.81 2.21 2.59
North West 772 17.88 27.46 12.20 2.15 1.24
Scotland 860 16.74 32.36 11.49 2.17 0.41
South East 429 22.80 20.28 16.79 2.19 2.21
South Midlands 573 29.81 58.01 18.86 2.35 1.06
South West 731 34.47 66.40 19.73 2.61 0.91
Trent 563 29.33 32.98 20.58 2.22 2.04
All regions 5678 24.69 40.65 16.30 2.29 0.41
aArithmetic mean. bGeometric mean. cExponential of the geometric standard deviation.
Table 17 Numbers of control houses in pre-defined categories of annual
average radon concentration (seasonally adjusted by region)
Average annual radon concentration (Bq m–3) n %
0–24 4173 73.5
25–49 1000 17.6
50–99 355 6.3
100–199 110 1.9
200 and over (‘action level’) 40 0.7
Total 5678 100.0respective UKCCS regional epidemiology centres to allow diag-
nostic data to be linked to the epidemiology data.
Pathology reports, and as appropriate, radiology reports were
obtained for all non-UKCCSG cases and for those UKCCSG cases
where this information was not appended to the registration form.
More than half of all solid tumour cases were entered into national
or international clinical trials. Special histopathological review is
automatically carried out for all such cases entered into trials and it
was agreed nationally that diagnostic review pathology reports for
them would be made available to the UKCCS. Members of the
pathology review panels associated with each clinical trial addi-
tionally agreed to review diagnoses of respective non-trial cases
eligible for the UKCCS. Collation of clinical trial diagnostic
review reports and organization and coordination of review of
non-trial cases nationally was carried out centrally for the UKCCS
at the CRC Paediatric & Familial Cancer Research Group
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Table 18 Interviewed cases by diagnostic group
Age/Sex
0 1–4 5–9 10–14 0–14
Diagnostic group M F M F M F M F M F
Unclassified 0 0 0 0 0 1 1 0 1 1
Hodgkin’s disease 0 0 8 1 26 9 50 24 84 34
Non-Hodgkin’s lymphoma 0 0 32 20 55 18 81 25 168 63
Unspecified lympho-reticular neoplasms 0 0 1 0 3 0 1 0 5 0
Total lymphoma and other lympho-reticular neoplasms 0 0 41 21 84 27 132 49 257 97
Pilocytic astrocytoma 3 5 21 34 34 37 17 19 75 95
Other low-grade astrocytomas 5 1 9 13 7 15 17 17 38 46
High-grade astrocytomas and glioblastomas 1 1 4 7 7 14 7 7 19 29
Other gliomas 1 2 8 6 17 19 8 5 34 32
Ependymoma 2 2 20 11 7 8 10 9 39 30
Choroid plexus tumours 7 3 4 4 1 0 1 0 13 7
Medulloblastoma 4 4 22 17 34 25 18 5 78 51
Other PNET 3 2 7 10 1 5 3 2 14 19
Other specified intracranial/intraspinal 2 2 9 7 13 12 7 7 31 28
Unspecified intracranial and intraspinal 0 0 1 1 0 3 1 2 2 6
Total CNS and misc intracranial and intraspinal 28 22 105 110 121 138 89 73 343 343
Retinoblastoma 22 16 25 19 2 2 1 0 50 37
Neuroblastoma and ganglioneuroblastoma 42 21 51 42 16 9 5 2 114 74
Peripheral neuroectodermal tumours – bone 0 1 2 2 6 5 17 10 25 18
Peripheral neuroectodermal tumours – extraskeletal 1 2 4 2 5 6 6 9 16 19
Total peripheral neural tumours 43 24 57 46 27 20 28 21 155 111
Wilms’ tumour 12 5 62 60 17 18 4 4 95 87
Renal carcinoma 0 0 0 0 0 0 2 3 2 3
Other specified renal tumours 3 1 2 2 4 0 0 0 9 3
Total renal tumours 15 6 64 62 21 18 6 7 106 93
Hepatoblastoma 5 5 11 4 0 1 2 0 18 10
Hepatic carcinoma 0 0 0 0 1 2 0 1 1 3
Total hepatic tumours 5 5 11 4 1 3 2 1 19 13
Osteosarcoma 0 0 0 3 11 8 17 17 28 28
Chondrosarcoma 0 0 0 0 0 0 1 1 1 1
Embryonal rhabdomyosarcoma 2 3 30 19 19 11 7 4 58 37
Alveolar rhabdomyosarcoma 1 1 7 4 1 3 2 3 11 11
Other and unspecified rhabdomyosarcoma 1 0 4 3 2 4 1 1 8 8
Other specified bone tumours 0 1 0 0 1 0 1 0 2 1
Intracranial & intraspinal soft tissue tumours 0 0 0 3 0 0 0 0 0 3
Other specified soft tissue tumours 3 4 6 1 10 6 11 9 30 20
Unspecified soft tissue tumours 1 1 4 1 3 1 4 0 12 3
Total sarcomas and other mesenchymal tumours 8 10 51 34 47 33 44 35 150 112
Gonadal germ cell tumours 4 0 14 2 0 5 5 5 23 12
Intracranial & intraspinal germ cell tumours 3 1 1 2 2 3 17 8 23 14
Other non-gonadal germ cell tumours 3 2 3 12 1 1 1 1 8 16
Gonadal carcinoma 0 0 0 0 1 0 0 1 1 1
Total germ cell, trophoblastic and other gonadal tumours 10 3 18 16 4 9 23 15 55 43
Adrenal cortical carcinoma 0 0 0 2 0 1 0 1 0 4
Nasopharyngeal carcinoma 0 0 0 0 1 0 3 0 4 0
Thyroid carcinoma 0 0 0 0 2 0 1 1 3 1
Melanoma 0 0 0 4 4 8 4 7 8 19
Non-melanoma malignant neoplasms of skin 0 0 0 0 0 0 1 4 1 4
Other carcinoma NEC 0 0 0 0 1 1 3 4 4 5
Pancreatoblastoma and (pleuro) pulmonary blastoma 0 0 1 2 0 0 0 0 1 2
Other specified rare tumours 0 0 0 0 0 1 0 0 0 1
Total rare miscellaneous neoplasms 0 0 1 8 8 11 12 17 21 36
Unspecified malignant neoplasms NE 1 2 0 1 0 3 0 1 1 7
Langerhan’s cell histiocytosis 6 2 11 9 9 7 3 2 29 20
Total all cases 138 90 384 330 324 274 343 221 1189 915(PFCRG) in Manchester. Pathology review panels for Hodgkin’s
disease, non-Hodgkin’s lymphoma, brain tumours, neuroblastoma,
renal tumours, liver tumours, bone tumours, soft tissue sarcoma
and germ cell tumours were already set up in association with clin-
ical trials. An additional pathology panel was set up to review
diagnoses of the remaining rare tumour groups. Thus, the diag-
noses of all cases both clinical trial and non-clinical trial were
reviewed by the same specialist panels.
Following receipt of registration details, confirmation of eligi-
bility for UKCCS and ascertainment of a UKCCS registration
number, clinical trial status was obtained from the UKCCSG Data
Centre. For non-trial cases, histopathology material was requested
by the coordinating centre in Manchester from the relevant consul-
tant pathologists. Tissue sections were cut and mounted, and
distributed to the appropriate diagnostic panel in accordance with
the panel’s requirements. Consensus reports were prepared on
each case by the review panels and reports sent to the Manchester
centre in due course. For trial cases a similar review process was
followed but this was coordinated by the UKCCSG Data Centre in
Leicester. For these latter cases, copies of the consensus pathology
panel reports were provided to the coordinating centre in
Manchester. These reports constitute the final reviewed diagnosis
on each case.
Diagnoses were coded according to ICD-O2 and entered
together with identification and other registration details onto the
histopathology database held in Manchester. A hierarchical confir-
mation of diagnosis code was also allocated as follows:
1. special histopathological review (trial and non-trial)
2. review at UKCCSG member centre or other specialist onco-
logical or neuropathology centre and pathology report received
in Manchester
3. other pathology report received in Manchester
4. diagnosis histologically confirmed but pathology report not
seen in Manchester
5. no histological confirmation but positive biological marker
6. clinical diagnosis with radiology report seen in Manchester
7. clinical diagnosis radiology report not seen in Manchester,
8. UKCCS registration form or notification from CCRG in
Oxford with no accompanying pathology or radiology report.
Each case was allocated to a main diagnostic group and sub-
group within the main group according to the classification
scheme described below.
Diagnostic classification scheme for childhood cancers
In formulating the classification scheme priority was given to allo-
cating individual tumour types to diagnostic groups on the basis of
what is currently known about the histogenesis and biology of the
tumours. The following features were incorporated into the
scheme: (i) the more common types of childhood malignancies
were specified as individual categories, (ii) rare tumours of partic-
ular biological interest were also individually specified, (iii) diag-
nostic categories were organized in a hierarchical way to allow
major groups to be sub-divided into sub-groups and where appro-
priate into sub-categories within sub-groups. This allowed flexi-
bility with regard to the diagnostic specificity with which data may
be analysed and presented while retaining a standard framework.
For each morphological entity, or group of entities defined by
ICD-O M codes, a set of corresponding topography codes was also
defined. A computer data input routine was developed such that
only compatible paired M and T codes would be accepted and
incompatible M and T codes would be unclassified. This arrange-
ment acts as an automatic check at the data input stage on the accu-
racy of information received on morphology and primary site of
tumours and the accuracy of coding. Furthermore, by these means
common data input errors such as reversal of two digits would be
detected at the outset. The draft scheme was tested on the
Manchester Children’s Tumour Registry database which was
already coded in ICD-O2. Primary information on those cases that
were not classified to a diagnostic group was checked and incon-
sistencies in the allocation of M and T codes within the draft
scheme were corrected. The final scheme and accompanying data
input programme were then used for the UKCCS diagnostic data.
The UKCCS case series includes some relatively recently
described diagnostic entities for which ICD-O codes do not exist.
Where it was thought that no appropriate alternative code existed,
it was necessary to create a small number of new codes and to
incorporate these into the classification scheme. The final scheme
comprises 11 major diagnostic groups with a total of 45 sub-
groups. The distribution of interviewed cases included in UKCCS
according to this classification scheme is shown in Table 18.
Detailed results of the histopathology review will be presented
elsewhere (Birch and Kelsey et al, in preparation).
LEUKAEMIA: BIOLOGICAL SAMPLES AND
CLASSIFICATION
Rationale of classification
The acute leukaemias have been traditionally classified by
morphological and cytochemical criteria into lymphoblastic
(ALL) and myeloblastic (AML) sub-classes for diagnostic and
treatment purposes (Henderson et al, 1996). Beginning in the
1970s, it became apparent that these two broad divisions disguised
considerable biological heterogeneity. Subsequently, immuno-
phenotypic and chromosomal variations (structural or numerical)
were identified and standardized using monoclonal antibodies
(Greaves et al, 1985; van Dongen and Adriaansen, 1996) and G-
banded chromosome analysis (Pui et al, 1993; Raimondi, 1993)
respectively. Over the past decade, changes in individual genes
(rearrangements/fusions, mutations, deletions, etc) have been
recognized and have provided a further hierarchical tier of
leukaemia classification (Greaves, 1996a). The validity of this
biological approach has been endorsed by the finding that subsets
so defined had different prognostic outcomes in the context of
particular therapies (Kersey, 1997; Pui and Evans, 1998). The
design of current therapeutic trials or patient selection for bone
marrow transplantation now exploits these biological classifica-
tions.
As acute leukaemia in children (and in adults) is not a single
biological entity or disease, it seems highly improbable that its
aetiology will be attributable to a single causal mechanism.
Epidemiological case–control studies in the past have mostly
divided cases into myeloid or lymphoid (the ICD system).
Although both ALL and AML as well as CML may be initiated by
ionizing radiation, there are several precedents in haematological
malignancy for more selective or preferential aetiological associa-
tions. These include HTLV1 with mature T-cell leukaemia/
lymphoma, EBV with Burkitt-like B-NHL, benzene with AML,
certain genotoxic therapeutic agents with AML (Henderson et al,
1996; Smith et al, 1996; Greaves, 1997). The incidence rates or
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especially with respect to the age peak of incidence in ALL at
2–5 years of age which consists of B-cell precursor ALL or
common c-ALL (Greaves et al, 1985, 1993). The prominence of
height of this peak in different countries has changed asynchro-
nously during the past 60 years (Greaves et al, 1985, 1993) and
although changes in ascertainment or diagnosis may have
contributed to this, c-ALL has been proposed as having a distinct
infectious aetiology in which social circumstances modulate
patterns of exposure (Greaves, 1997). c-ALL in turn is heteroge-
neous by molecular genetic criteria but two large subgroups
predominate – hyperdiploidy and TEL (ETV6)-AML1 (CBFA2)
gene fusion (Bernard et al, 1996; Secker-Walker, 1997).
Age is a prognostic factor in ALL and it is now recognized that
the higher risk groups of ALL below 1 year of age or above 10
years seldom have the common molecular characteristics of c-
ALL in the 2- to 5-year age peak. Infants (< 1 year) in particular
appear to have a distinct biological subtype of disease in which
translocations at 11q23 are predominant. These generate fusions of
the MLL gene with partner genes on other chromosomes, espe-
cially AF4 (at 4q) (Pui et al, 1995; Greaves, 1996b). Similar
translocations involving 11q23/MLL (but with different partner
genes) are common in paediatric AML, particularly below the age
of 3 years. 11q23/MLL gene fusions are also frequent in secondary
leukaemias arising from prior therapeutic exposure to drugs that
inhibit the enzyme topoisomerase II. On this basis it has been
proposed that transplacental exposure to chemically similar
compounds in utero might provide a selective causal pathway for
infant AML and ALL with 11q23/MLL rearrangements (Ross et al,
1994b; Greaves, 1997). Some prior epidemiological data suggest
selective associations for acute leukaemia, and especially AML, in
very young (< 2 years) patients (Ross et al, 1994a).
These data and insights all suggest that it would be prudent
whenever possible to incorporate biological classification into
epidemiological studies of leukaemia. This is only worthwhile,
however, when studies are of a sufficient size to generate adequate
numbers in the smaller subgroups.
This is the first large case–control study where a systematic
biological classification has been undertaken. Of the five major
hypotheses under discussion (see p. 1074), those involving EMF
and ionizing radiation do not involve any prior consideration of
biological subsets of ALL. With respect to chemical exposures (in
utero) and infection, however, we have identified biological
subgroups in advance for which selective associations will be
sought (e.g. delayed infection and HLA associations in c-ALL).
As diagnostic samples of acute leukaemia were referred to a
central reference laboratory (see below) for molecular genetic
analysis, it was also decided to use whatever material remained
after the tests were completed to establish a sample bank. This is
designated for use in add-on studies related to our major
hypothesis (e.g. screening for viruses or for gene polymorphisms
by polymerase chain reaction (PCR) methods).
Materials and methods
Morphology
Individual haematologists in participating centres diagnosed ALL
and AML based on morphological, standard staining (PAS ±
Sudan Black ± non-specific esterase ± acid phosphatase stains)
and immunophenotyping. Central review was performed by a
panel of three haematologists as part of the MRC therapy trials
protocol. This panel ascribed individual patients to an appropriate
French–American–British morphological classification type; for
ALL into L1, L2 or L3; for AML into M0–M7 (Catovsky et al,
1991; Lilleyman et al, 1992).
Immunophenotyping
In 1989–1990, following national consensus meetings on the
optimal battery of monoclonal antibodies required for appropriate
immuno-phenotypic diagnosis of ALL, a series of workshops were
held to produce consistent quality of performance in such testing,
prior to the commencement of the MRC UKALL XI trial which
ran throughout the period of the National Case Control Study.
Thereafter centres admitting patients to the MRCs ALL trials were
requested to perform a standard panel of immunophenotyping tests
(Hann et al, 1998), which included anti-CD2, CD7, CD10, CD13,
CD19, CD33, CD34 and HLA-DR as well as testing for terminal
deoxynucleotidyl transferase (TdT) and for cytoplasmic
immunoglobulin. The latter (cyto m) data have not been used for
the classification scheme reported here.
In line with international agreement, a cut-off point for posi-
tivity was taken at ³ 30% for CD2, CD7, CD19 and CD34.
Patients were investigated by all 98 participating physicians using
the same panel, but 42% of laboratories used flow cytometry
analysis, 38% alternative methods in addition to flow cytometry
and 20% used no flow cytometry and used only alternative
immunophenotyping techniques (fluorescence microscopy,
immunohistochemistry).
Cases of ALL were classified by immunophenotype into B-cell
lineage or T-cell lineage subtypes. Cases that could not be unam-
biguously defined because of incomplete data or mixed lineage
phenotypes were classified as ‘Other’. Seven per cent of eligible
cases of ALL samples were not available for analysis.
Clinical presentation alone rarely provides clarity between the
diagnosis of ALL or AML. The same battery of morphological
staining and phenotyping was therefore performed on the majority
of patients with AML, with the addition of erythroid and
megakaryocyte antibody markers wherever appropriate. Central
morphological review was also performed by the panel for AML
cases.
Cytogenetics
Conventional G-banded cytogenetic analysis was performed on
diagnostic bone marrow and/or peripheral blood samples from
ALL and AML patients by local cytogenetic laboratories.
Cytogenetic data from patients entered to MRC treatment trials
were routinely collected by two national databases: the Leukaemia
Research Fund UK Cancer Cytogenetics Group ALL Karyotype
Database (ALL Database) and the Kay Kendall Leukaemia Fund
Childhood AML Karyotype Database (AML Database). Slides are
reviewed before the karyotypes are entered to the ALL Database,
and all karyotypes are written according to the International
System for Human Cytogenetic Nomenclature (ISCN, 1995).
Cytogenetic data were then provided directly from the ALL and
AML Databases to the UKCCS.
Molecular diagnostics and cell/DNA/plasma banks
Pretreatment biological samples from leukaemia and non-
leukaemia cancer cases were referred to a single centre and entered
into a FoxPro database. Of the 1711 leukaemia cases (ALL plus
AML) entered into the study, biological samples were received
from 1153. For the 2102 non-leukaemic cancers registered and
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samples consisted of up to 5 ml of peripheral blood (with anti-
coagulant) and/or up to five bone marrow smears. Blood only was
received from non-leukaemic cancers.
On receipt of samples, slides were individually wrapped in
foil and stored at – 70°C. Plasma was separated from blood by
centrifugation, aliquoted and stored at –2°C or –70°C.
Mononuclear cells were separated over a density gradient and
counted. In cases with a low yield of cells from blood (< 106) the
cells were either pellet frozen in liquid nitrogen or stored in guani-
dinium isothiocyanate (GIT) solution for subsequent RNA prepa-
ration. For higher yield cases (> 106), some cells were control
frozen in liquid nitrogen as viable cells (and as a source of DNA)
and an aliquot stored in GIT.
Detection of TEL(ETV6)-AML1 (CBFA2) RNA was reverse
transcribed to generate cDNA, the integrity of which was assessed
by reverse transcriptase PCR (RT-PCR) amplification of a house-
keeping gene (c-ABL). Screening for (TEL-AML1) by RT-PCR
was with a single pair of primers as described previously (Romana
et al, 1995). Fifty cases that had been investigated for evidence of
the TEL-AML1 fusion by RT-PCR (see below), were also indepen-
dently tested by interphase fluorescence in situ hybridization
(FISH) using dual colour probes (Vysis, UK) in the cytogenetics
reference laboratory (C Harrison, Royal Free Hospital, London).
FISH revealed six TEL-AML1-positive cases, which had not been
detected by RT-PCR (and one case was negative by FISH, which
had been found to be positive by RT-PCR).
RT-PCR was also used to screen for the t(1;19) (E2A-PBX),
t(9;22) (BCR-ABL) translocations and for translocations of MLL
with AF4, AF6, AF9 and ENL (Repp et al, 1995). These tests used
nested primers with high sensitivity (10–4/10–5). These latter
screens produced an unacceptable level of false-positives (and
some false-negatives) and therefore karyotype alone was used for
the final molecular classification based upon these three types of
translocations. Deletion of the TAL gene in cases of T-ALL was
detected by direct PCR using a single set of primers as previously
described (Janssen et al, 1993). A subset of ALL cases with high
white cell counts were also assayed for deletion and methylation
of the cell cycle inhibitor genes CDKN2/p16INK4A and
CDKN1/p15INK4B. These data were not, however, incorporated into
the final molecular diagnostic scheme and are reported in detail
elsewhere (Iravani et al, 1997).
FISH detection of ploidy changes Cases that were registered as kary-
otypically normal or failed in the LRF/UK Cancer Cytogenetics Study
Group Database (see above) were screened (by the molecular genetics
reference laboratory) by interphase FISH for extra copies of chromosomes
X and 21 using chromosome specific probes. The presence of extra copies
of both X and 21 was required to define hyperdiploidy. These two chromo-
somes were selected as our pilot study and published reports (Moorman et
al, 1996; Raimondi et al, 1996) indicated that > 90% of cases of ALL that
are high hyperdiploid include additional copies of both 21 and X.
Sample banking Material remaining on some patients after
molecular screening included bone marrow smears, plasma and
small quantities of cells, RNA, cDNA and DNA suitable for PCR-
based assays. These have been stored for future studies.
Results and discussion
A haematological and immunophenotypic subdivision of all
patients eligible for the study and interviewed is given in Table 19.
Non-Hodgkin’s lymphoma data are given separately in Table 18
but we note here there is a biological and clinical case for T-NHL
and T-ALL being subtle manifestations of essentially the same
thymic or T-cell precursor malignancy. They may therefore be
pooled together in later analyses. Similarly, rare cases of FABL3
Burkitt-like ALL (mature B immunophenotype) are more ratio-
nally grouped along with B-NHL.
Figures 7A, 7B and 8 show the breakdown of cases according to
the major cytogenetic and molecular genetic abnormalities.
Molecular genetic diversity in acute leukaemia is extensive;
indeed in complete detail it is likely that every patient has a
distinct molecular pattern of clonal diversity. A substantial number
of patients had either infrequently occurring chromosomal abnor-
malities or highly complex karyotypes in which none of the
common chromosomal abnormalities were identified; these were
grouped together under ‘Others’. Some chromosomal deletions
appear to occur relatively commonly in different immunological
subtypes and in conjunction with other molecular changes, for
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Table 19 ALL and AML immunophenotypes
ALL AML Overall total
B-cell T-cell Other Not done
Common Pro-B
Sex
Boys 512 (56.7)a 22 (45.8) 90 (65.7) 141 (51.8) 55 (54.5) 134 (53.6) 954 (55.8)
Girls 391 (43.3) 26 (54.2) 47 (34.3) 131 (48.2) 46 (45.5) 116 (46.4) 757 (44.2)
Age at diagnosis
0 20 (2.2) 22 (45.8) 1 (0.7) 7 (2.6) 0 (0) 35 (14.0) 85 (5.0)
1 64 (7.1) 3 (6.3) 7 (5.1) 15 (5.5) 7 (6.9) 36 (14.4) 132 (7.7)
2–5 570 (63.1) 9 (18.7) 50 (36.5) 145 (53.3) 53 (52.5) 58 (23.2) 885 (51.7)
6–14 249 (27.6) 14 (29.2) 79 (57.7) 105 (38.6) 41 (40.6) 121 (48.4) 609 (35.6)
Down’s syndrome 17 (1.9) 0 (0) 0 (0) 5 (1.8) 2 (2.0) 15 (6.0) 39 (2.3)
Total 903 (66.4)b 48 (3.5)b 137 (10.0)b 272 (20.0)b 101 250 1711
aPercentages of cases (in vertical columns). bPercentages of classified cases (in horizontal rows).example deletion of the long arm of chromosome 6 [del(6q–)] or
the short arms of chromosomes 9 and 12 [del(9p), del(12p)]. It is
suspected, though unproven, that these may be secondary changes
associated with disease progression and although we have these
data available for subsequent analysis, we have not incorporated
them here for classification purposes.
The numbers in some molecularly defined subgroups in this
study are small which will restrain the statistical strength of any
subsequent analyses; however, some highly selective associations
may emerge. Two subgroups are of appreciable size – the c-ALL
with either hyperdiploidy (423) or TEL-AML1 fusion (139). These
data should enable us to assess whether any epidemiological
associations found for ALL are more pronounced within these
molecularly defined subgroups.
Age and gender
As age and gender have been shown to be of some prognostic
importance in leukaemia clinical trials (Kersey, 1997) and some
biologically defined subgroups are already known to have a
marked age and/or gender bias (Greaves et al, 1985; Greaves,
1999), we also summarize here, in Figures 9–13, the age distribu-
tions within the UKCCS data set of the major biological subsets
and in Tables 19 and 20 provide a breakdown according to gender
and broad age groupings.
MOLECULAR ANALYSIS OF GENETIC
SUSCEPTIBILITY
There is now increasing recognition that genetic susceptibility
can influence the risk of childhood cancer (Perera, 1997).
Identification of genes that increase susceptibility might therefore
help to pinpoint the role of specific carcinogens (Suk and Collman,
1998). To facilitate studies of genetic susceptibility, the UKCCS
has involved the systematic collection of post-treatment blood
samples from children with cancer, and, as healthy controls, from
their parents, sibs and unrelated children. In the first instance the
molecular analysis has involved comparisons of HLA class II
(DPB1, DQA1, DQB1) allele frequencies in cases and controls for
evidence of allele associations that could, in conjunction with
epidemiological data, provide support for the role of infection in
the aetiology of childhood leukaemia and lymphoma. Since no
previous study of childhood cancer in the UK has involved the
collection of post-treatment blood samples from children with
cancer on a national scale, this paper presents details of the
methods used, reviews sample collection, and provides brief
details of the HLA typing methodology.
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Figure 8 Cytogenetic and molecular genetics classification of AML casesMethods and results
Blood sample collection
The methods used in the molecular epidemiological analysis are
summarized in Figure 14. The systematic collection of post-treat-
ment blood samples from children with cancer, their parents and
siblings was carried out by UKCCS interviewers, in paediatric
oncology clinics and by GPs. Factors affecting sample retrieval
included patient survival, and parental consent. Samples were
obtained in remission from children with leukaemia, and post-
therapy from children with lymphoma and solid tumours, when
white cell counts had recovered to provide sufficient DNA. Samples
from children with leukaemia, lymphoma and cancer usually
consisted of blood (~5 ml) in EDTA for the extraction of genomic
DNA. Samples (~5 ml) from children with leukaemia and
lymphoma were also collected in preservative-free heparin (~5 ml)
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Figure 9 Frequency distribution of all ALL cases by single years of age Figure 10 Frequency distribution of TEL-AMLI cases by single years of age
Table 20 Molecular cytogenetics in ALL cases (excluding those classified as T-ALL)
Hyperdiploid TEL-AML1 Other abnormality ‘Normal’ Unknown Overall total
Sex
Boys 241 (57.0)a 74 (53.2) 157 (49.7) 84 (62.2) 174 (56.0) 730 (55.1)
Girls 182 (43.0) 65 (46.8) 159 (50.3) 51 (37.8) 137 (44.1) 594 (44.9)
Age at diagnosis
0 0 (0) 0 (0) 30 (9.5) 2 (1.5) 17 (5.5) 49 (3.7)
1 29 (6.9) 6 (4.3) 22 (7.0) 9 (6.7) 23 (7.4) 89 (6.7)
2–5 271 (64.1) 95 (68.3) 156 (49.4) 84 (62.2) 171 (55.0) 777 (58.7)
6–14 123 (29.1) 38 (27.3) 108 (34.2) 40 (29.6) 100 (32.2) 409 (30.9)
Down’s syndrome 5 (1.2) 1 (0.7) 5 (1.6) 6 (4.4) 7 (2.3) 24 (1.8)
Total 423 139 316 135 311 1324
aPercentage of cases (in vertical column).
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Figure 11 Frequency distribution of C-ALL cases by single years of age
Figure 12 Frequency distribution of hyperdiploidy cases by single years of
ageto retrieve viable lymphoid cells. Samples (~10 ml) from the parents
and siblings of children with leukaemia or lymphoma were collected
in the same way. Samples from the parents and siblings of children
with solid tumours were collected in EDTA only.
Blood sample collection commenced in 1992, and continued until
the end of 1997. The aim was to obtain as complete a set of samples
from eligible index case children, and their parents and siblings as
circumstances would allow. Genomic DNA was extracted from all
blood samples since it provides the most robust and versatile source
of biological material for the direct molecular analysis of genetic
susceptibility. The PCR was used in the molecular analysis because
it conserves DNA whilst allowing genetic screening to be carried
out at high resolution. Since the amount of blood sample obtained
was limited, viable lymphoid cells from children with leukaemia
and lymphoma were frozen with the objective of preparing
lymphoid cell-lines as an additional source of material.
Sample processing and storage
Each child with cancer from whom a blood sample was received
was assigned a unique laboratory code, and together with the
child’s name, diagnosis and other identifiers, this was entered into
a Microsoft Access database. Information about relatives (parents,
siblings) of the child with cancer from whom a sample was
obtained was also recorded in the database. Genomic DNA was
extracted from all blood samples using a resin-based commercial
kit (BACC2, Nucleon), the DNA diluted to 50 ng ml–1, and stored
at – 80°C. Lymphoid cells were isolated from the blood of children
with leukaemia and lymphoma and from their parents by centrifu-
gation over Lymphoprep (Nycomed), and stored in a viable state in
liquid nitrogen.
Blood samples from children with cancer
Post-treatment blood samples were obtained from 1863 (48%) of
the 3838 children eligible for the UKCCS. These included samples
for 1183 (68%) of the 1736 children with leukaemia, 181 (51%) of
the 349 children with lymphoma (Hodgkin’s and non-Hodgkin’s),
and 499 (28%) of the 1753 children with solid tumours.
Family controls
Where possible, blood samples were collected from both bio-
logical parents of each child with cancer for the purpose of
providing family-based controls. Samples were obtained from
both parents of 846 (48%) of the eligible children with leukaemia,
131 (37%) of those with lymphoma and 301 (17%) of those with
solid tumours. Blood samples were obtained from the healthy sibs
of 719 of the children with cancer. These included 426 sibs of
children with leukaemia, 91 sibs of children with lymphoma and
202 sibs of children with solid tumours.
Unrelated childhood controls
Ethical considerations precluded the collection of blood samples
from UKCCS case-matched control children. Children with other
types of cancer were therefore used as controls for any specified
type of cancer (for example, children with solid tumours served as
controls for children with leukaemia). In the absence of an
adequate national sample of case-matched control children without
cancer, data from 1500 full-term healthy newborn babies delivered
in St Mary’s Hospital, Manchester were additionally used as a
provisional comparison group.
Molecular analysis
The molecular analysis (Figure 14) set out to compare allele,
phenotype, and haplotype frequencies between children with
different types of cancer, and with parental, sib or unrelated
controls at three HLA class II loci (DPB1, DQA1, DQB1) loci.
Using genomic DNA, exon 2 of HLA-DPB1, DQA1 or DQB1 was
amplified in the polymerase chain reaction using locus-specific
primers (Fernandez-Vina and Bignon, 1997). The amplified PCR
products were arrayed at high density by dot-blotting onto repli-
cate nylon membranes using a Beckman Biomek 2000, and the
membranes hybridized with 32P-labelled sequence specific
oligonucleotides (SSO). The membranes were scanned for
hybridization with SSO probes on a Packard InstantImager, and
alleles assigned to each individual based on patterns of positive
and negative SSO probe reactions for each locus.
The HLA-DPB1, DQA1 and DQB1 type of each subject was
stored in the Microsoft Access database, and data relevant for the
analysis of HLA associations collated in Access Queries for
output into Microsoft Excel files. These were used to compute
allele, genotype and phenotype frequencies for each diagnostic
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Figure 14 Flow diagram showing steps in the molecular screening of index
cases and controls for HLA class II allelescase and control series. Associations with specific HLA alleles
were expressed as odds ratios with 95% confidence intervals 
(CI), and the significance of differences between different groups
in Fisher’s two-sided exact test, with appropriate Bonferroni
corrections.
Discussion
It is increasingly recognized that the aetiology of childhood cancer
involves pre- or early post-natal exposure to environmental
carcinogens and a host response modulated both by developmental
and inter-individual genetic variations. The identification of
constitutional variations in specific genes involved in the metabo-
lism of carcinogens offers a way of predicting the aetiological role
of a given environmental factor.
The UKCCS has included the systematic collection of post-
treatment blood samples from children with cancer and from
related and unrelated controls for molecular studies of variations
in cancer susceptibility. The primary aim of these studies was
to analyse the frequency of HLA class II alleles in childhood
leukaemia and lymphoma. An allele association could be
construed as supporting the hypothesis of an immune-mediated,
possibly infectious, aetiology in childhood leukaemia/lymphoma
(Greaves, 1999). Existing evidence for the role of HLA class II
alleles in susceptibility to childhood leukaemia and lymphoma is
limited to small patient series (Taylor et al, 1998). Although the
UKCCS has involved much larger patient and control series,
logistic considerations required the development of a high-
throughput HLA typing method. This included the batchwise
amplification with HLA locus-specific PCR primers and the
analysis of SSO hybridization by automated scanning.
The molecular screening of genetic variations in cases
compared with controls is becoming a more widely accepted part
of epidemiological studies. Molecular methods are able to identify
inter-individual genetic variations that may influence childhood
cancer susceptibility with remarkable precision. The intrinsically
difficult assessment of environmental exposures in relation to the
risk of childhood cancer is thus complemented by data on inter-
individual genetic variations in carcinogen-response genes that
may help to define susceptible patient groups. Careful selection of
candidate genes with known functions and sound aetiological
hypotheses reduces the empirical nature of this analysis. The
development of high-throughput micro array-based assays offers
an opportunity for testing the role of given genetic variations in
statistically robust patient and control groups. The collection of a
comprehensive series of post-treatment blood samples from chil-
dren with cancer as part of the UKCCS shows that this can be
achieved as part of a comprehensive epidemiological study.
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